(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 23 October 2003 (23.10.2003)

PCT

(10) International Publication Number WO 03/087399 A1

- (51) International Patent Classification?: A61K 31/03, 31/12, A61P 3/10
- C12Q 1/26,
- (21) International Application Number: PCT/SE03/00618
- (22) International Filing Date: 16 April 2003 (16.04.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0201152-6 60/410,626 17 April 2002 (17.04.2002) SE 13 September 2002 (13.09.2002) US

- (71) Applicant (for all designated States except US): BIOVIT-RUM AB [SE/SE]; S-112 76 Stockholm (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GRÖNBERG, Alvar [SE/SE]; Tuvstarrvägen 7, S-741 42 Knivsta (SE). WIKSTRÖM, Per [SE/SE]; Tegelvägen 1 b, S-194 36 Upplands Väsby (SE).

- (74) Agent: HÖGLUND, Lars; Biovitrum AB, S-112 76 Stockholm (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CII, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

A1

(54) Title: NAD)P)H OXIDASE INHIBITORS FOR INCREASED GLUCOSE UPTAKE AND TREATMENT OF TYPE II DIABETES

(57) Abstract: The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

10

15

20

25

30

NAD(P)H Oxidase inhibitors for increased glucose uptake and treatment of type II diabetes.

TECHNICAL FIELD

The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes.

BACKGROUND ART

A large number of people suffer, or are predisposed to suffer from disturbances in their metabolism. One such disturbance includes insulin resistance, which is characteristic of the metabolic syndrome (syndrome X), polycystic ovary syndrome, obesity and type II diabetes, diseases that are rapidly growing in number in the western world. These diseases are multi-factorial and their mechanism or physiology are, in the majority of cases, not well characterized or understood. Type II diabetes includes the most prevalent form of diabetes, which results from insulin resistance with an insulin secretory defect. Pharmacological treatments such as metformin and rosiglitazone have an ameliorating effect on insulin resistance and are believed to increase the effectiveness of endogenous insulin and thereby contribute to the lowering of elevated blood glucose levels in type II diabetes patients.

One mechanism whereby insulin resistance may be induced is via elevation of reactive oxygen species (ROS). Although contrasting effects of ROS have been reported on the insulin signal transduction system and glucose transport, it has been shown that prolonged exposure of cells to ROS causes insulin resistance. Insulinomimetic effects of ROS have been reported using muscle cells and adipocytes. Acute exposure of adipocytes to H₂O₂ was shown to activate pyruvate dehydrogenase activity and lipid synthesis [May et al., Journal of Biological Chemistry, 254:9017-21 (1979)]. Some but not all aspects of insulin signaling appear to be activated by H₂O₂. Using L6 myocytes it was shown that H₂O₂ caused a PI3K-dependent activation of PKB and inhibition of GSK3 within 30 min of treatment [Tirosh et al., Journal of Biological Chemistry, 274:10595-602 (1999)]. Prolonged treatment (24 h) of L6 muscle cells and 3T3-L1 adipocytes with a ROS generating system increased the expression of GLUT1 that resulted in elevated basal glucose transport [Kozlovsky et al., Free Radical Biology & Medicine, 23:859-69 (1997); Kozlovsky et al., Journal of Biological Chemistry,

272:33367-72 (1997)]. Treatment of these cell lines with H₂O₂ also interferes with insulin signaling [Rudich et al., American Journal of Physiology, 272:E935-40 (1997)]. Simultaneous treatment with insulin and H₂O₂ was shown to inhibit insulin stimulated glucose transport and glycogen synthesis in spite of intact PKB activation [Blair et al., Journal of Biological Chemistry, 274:36293-9 (1999)]. Pretreatment with ROS inhibited insulin stimulated IRS-1 and PI3K cellular redistribution, PKB serine phosphorylation and glucose transport [Tirosh, Potashnik et al., Journal of Biological Chemistry, 274:10595-602 (1999)]. The antioxidant lipoic acid could prevent these effects [Rudich et al., Diabetologia, 42:949-57 (1999)]. Taken together, these results suggest that insulin signaling involve redox reactions, with some steps that can be mimicked and some that can be inhibited by H₂O₂. Integrating these findings with the demonstration that insulin can stimulate the production of H₂O₂, it can be hypothesized that ROS are involved in insulin signaling and may be responsible for the insulin resistance observed after prolonged treatment with insulin and other agents.

10

15

20

25

30

Oxidative stress is caused by excess free radical production in cellular metabolism. The free radicals derived from reaction products of oxygen are often termed reactive oxygen species (ROS). A reducing environment inside the cell prevents oxidative damage and can be maintained by the action of antioxidant enzymes and substances, such as superoxide dismutase (SOD), catalase, glutathione, selenium-dependent glutathione, thioredoxin hydroperoxidases, thioredoxin, vitamins C and E, and probably more unknown players.

Oxidative stress has been demonstrated in several different diseases and is implicated as an important driving force in the aging process [Finkel et al., Nature, 408:239-47 (2000); Spector, Journal of Ocular Pharmacology & Therapeutics, 16:193-201 (2000)]. A growing body of data demonstrate signs of increased oxidative stress in type II diabetes. It is likely that the oxidative stress is contributing to many of the vascular complications occurring in the late stages of the disease but the evidence for oxidative stress as causative factor in the development of insulin resistance and deterioration of beta cell function is still lacking. An inverse relationship between insulin action on glucose disposal and plasma superoxide ion, and a positive relationship between insulin action on glucose disposal and plasma GSH/GSSG ratio have been observed in type 2 diabetic patients during euglycemic hyperinsulinemic clamp [Paolisso et al., Metabolism: Clinical & Experimental, 43:1426-9 (1994)].

Decreased serum vitamin E content, a marker of impaired oxidant/antioxidant status,

was reported to be associated with increased risk of developing type II diabetes [Salonen et al., BMJ, 311:1124-7 (1995)]. In animal experiments it was recently demonstrated that chemically induced oxidative stress exacerbated insulin resistance and hyperglycemia in obese Zucker rats [Laight et al., British Journal of Pharmacology, 128:269-71 (1999)]. There are also indications that beta cell toxic agents like alloxan and streptozotocin that are used to induce experimental animal diabetes act via oxidative stress [Davis et al., Biochemical Pharmacology, 55:1301-7 (1998); Hotta et al., Journal of Experimental Medicine, 188:1445-51 (1998)].

5

10

15

20

25

30

Superoxide can be produced by a number of cellular enzyme systems: NAD(P)H oxidases, xanthine oxidase, lipoxygenases, cyclooxygenase, P-450 monooxygenases, and the enzymes of mitochondrial oxidative phosphorylation. The majority of free radicals are produced by the mitochondria as unwanted by-products of the respiratory chain but the cell also purposely generates free radicals. The cellular defense system of the body utilizes oxygen radicals to kill invading microorganisms and the vascular system uses the nitric oxide radicals as an intermediate in the regulation of vascular tone. Originally, the NAD(P)H oxidase system responsible for production of superoxide that participates in bacterial killing was demonstrated in neutrophils and other phagocyte cells [Segal et al., Annals of the New York Academy of Sciences, 832:215-22 (1997)]. A growing number of experimental data from endothelial cells and other cell types show that ROS can be produced through activation of NAD(P)H-oxidase [Jones et al., American Journal of Physiology, 271:H1626-34 (1996); Krieger-Brauer et al., Journal of Biological Chemistry, 272:10135-43 (1997); Bayraktutan et al., Cardiovascular Research, 38:256-62 (1998)]. When activated, the NAD(P)H oxidase assembles at the plasma membrane and catalyses the single electron reduction of molecular O2 to superoxide (O2). In the presence of superoxide dismutase, O2 dismutates to hydrogen peroxide (H2O2) that can be converted to a hydroxyl radical (OH) in the presence of ferrous ions. The list of other free radicals originating from O2 that can be formed in the cell is longer, and will not be further discussed here. At least five proteins are required for the formation of an active NAD(P)H oxidase complex: the membrane bound cytochrome b558 and the cytosolic proteins, p47^{phox}, p67^{phox}, p40^{phox} and a small GTP-binding protein, Rac-1 or Rac-2 [Abo et al., Journal of Biological Chemistry, 267:16767-70 (1992); Babior, Advances in Enzymology & Related Areas of Molecular Biology, 65:49-95 (1992); Knaus et al., Journal of Biological Chemistry, 267:23575-82 (1992)]. Cytochrome b558 is a flavoprotein with an NAD(P)H-binding

WO 03/087399 PCT/SE03/00618

site and consists of two subunits, gp91 ^{phox} and p22 ^{phox} [Sumimoto et al., Biochemical & Biophysical Research Communications, 186:1368-75 (1992)].

The hypoglycemic agent diphenylene iodinium (DPI) has been shown to diminish the rate of mitochondrial respiration by inhibiting NADH dehydrogenase. Holland et al. (1973; J. Biol. Chem. 248: 6050-6056) discloses that the enzyme inhibition causes the hypoglycemic action by decreasing mitochondrial oxidation and the hepatic and whole body ATP content (See also Gatley, S.J. & Martin, J.L. (1979) Xenobiotica 9: 539-546). However, it has not been previously shown that agents which inhibit NAD(P)H oxidase would be useful for increasing the activity of the insulin receptor and/or the intracellular insulin-signaling pathway, and thereby be useful against insulin resistance.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig.1 is a graph depicting the effect of DPI on insulin stimulated glucose transport in L6 cells when treated with different concentrations (0.1–10 μ M) of DPI alone for 30 min or together with insulin (200 or 1000 nM) for additional 30 min.

10

15

20

25

30

Fig. 2 is a graph depicting the effect of H₂O₂ generated by glucose oxidase (GO) DPI stimulated glucose transport. Differentiated L6 cells were treated with 25 mU/ml GO for 30 min before addition of DPI. After additional 30 min, 200 nM insulin was added and glucose transport was measured after 30 min.

Fig. 3 is a graph depicting blood glucose concentrations during an insulin tolerance test in ob/ob mice treated for 4 days with daily i.p. injections of DPI, 1 mg/kg (n=7), or vehicle (n=8).

DISCLOSURE OF THE INVENTION

It has surprisingly been found that inhibition of NAD(P)H oxidase stimulates glucose uptake in rat skeletal muscle cells. A NAD(P)H oxidase complex is putatively involved in down-regulation of insulin signaling via generation of ROS. Thus, pharmacological inhibition of NAD(P)H oxidase activity should increase insulin signaling and restore insulin sensitivity. This surprising effect has not been seen previously and demonstrates the utility of the entire, or parts of, NAD(P)H oxidase complex, which generates ROS, as a tool for finding drugs that can be used for treating type II diabetes, specifically insulin resistance.

Consequently, in a first aspect this invention provides a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, said method comprising

(i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and

5

10

15

20

25

(ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.

The said medical condition is preferably associated with insulin resistance, such as, in particular, type II diabetes. One clinical definition of diabetes is the so-called fasting glucose level. A patient is diagnosed with diabetes if the amount of glucose is above 126 milligrams per deciliter (mg/dl) measured on two occasions. Impaired fasting glucose and impaired glucose tolerance are associated with the insulin resistance syndrome. An individual can be insulin resistant in the absence of fasting hyperglycemia if an oral glucose tolerance test with 75 g anhydrous glucose dissolved in water gives a 2 h plasma glucose value \geq 200 mg/dl in a test performed as described by WHO [World Health Organization, Tech. Rep. Ser., no. 727, (1985)].

In one embodiment of the invention, cells containing the NAD(P)H oxidase or the NAD(P)H oxidase complex may be brought into contact with inhibitors of the NAD(P)H oxidase or the NAD(P)H oxidase complex, followed by monitoring the glucose uptake by these cells, and comparing this activity with that of a the NAD(P)H oxidase or the NAD(P)H oxidase complex in the absence of inhibitor. Compounds that affect the glucose uptake of these cells are to be considered as potential drug candidates.

The NAD(P)H oxidase or NAD(P)H oxidase complex is preferably selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.

The proteins may be of any mammalian species, however, a preferred species is *Homo sapiens*. The nucleotide and amino acid sequences from *Homo sapiens* are disclosed in the enclosed sequence listing.

In one embodiment, the invention includes a method for identifying an agent
that increases glucose uptake by a cell. The method includes the following steps:
contacting a cell with a candidate agent that inhibits the activity of an NAD(P)H
oxidase or an NAD(P)H oxidase complex; measuring glucose uptake by the cell in the
presence of the candidate agent; and determining whether the candidate agent increases
glucose uptake by the cell.

10

15

20

25

30

The method can optionally include an additional step of comparing glucose uptake by the cell in the presence of the candidate agent with glucose uptake by a cell in the absence of the candidate agent.

PCT/SE03/00618

The method can optionally include a step of contacting the candidate agent with the NAD(P)H oxidase or the NAD(P)H oxidase complex and determining that the candidate agent inhibits the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex.

In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H oxidase or the NAD(P)H oxidase complex can optionally be selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

The cell can be, for example, a muscle cell or an adipocyte.

In some embodiments, the candidate agent is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

In another aspect, the invention features a method for increasing glucose uptake in a cell by contacting a cell with an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to increase glucose uptake by the cell. The cell can be, for example, a muscle cell or an adipocyte. The method can optionally include an additional step of detecting an increase in glucose uptake by the cell in response to the contacting of the cell with the inhibitor.

In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H oxidase or the NAD(P)H oxidase complex can optionally be selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

In some embodiments, the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

In another aspect, the invention provides a method for the treatment of a medical condition associated with elevated levels of blood glucose, comprising administering to a patient in need thereof an effective amount of an inhibitor or antagonist of NAD(P)H oxidase or NAD(P)H oxidase complex.

In one embodiment, the invention features a method for the treatment of a medical condition, including the following steps: selecting an individual diagnosed as having a medical condition characterized by elevated levels of blood glucose; and administering to the individual an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to reduce blood glucose levels in the individual.

5

10

15

20

25

30

The medical condition can be characterized by, for example, insulin resistance, a need for increased activity of the insulin receptor, and/or a need for increased activity of the intracellular insulin-signaling pathway.

In one example, the medical condition is diabetes, e.g., type II diabetes.

In some embodiments, the individual does not have and/or has not been diagnosed as having a disorder (e.g., atherosclerosis) characterized by a vascular injury, e.g., vascular hyperpermeability of endothelial cells. In addition, in some embodiments, the method does not include a step of evaluating a vascular injury (if present) in the individual before and/or after the administration of the inhibitor to the individual.

In some embodiments, the method includes an additional step of detecting a reduction in blood glucose levels in the individual in response to the administration of the inhibitor.

In one example, the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex. The NAD(P)H oxidase or the NAD(P)H oxidase complex can optionally be selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2. The nucleic acid and amino acid sequences of exemplary NAD(P)H oxidases and NAD(P)H oxidase complexes are described herein.

In some embodiments, the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

The inhibitor or antagonist can be identified according to the method as described above. Examples of known inhibitors or antagonists are those selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate,

chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride and acetovanillone, including derivatives thereof. The said inhibitor or antagonist is e.g. a compound having an inhibitory effect on the ROS generating activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex. The inhibitor or antagonist could exert its effect by interacting with the active site or a regulatory site, or both sites, of the NAD(P)H oxidase.

A compound that shows the desirable characteristics with regards to inhibiting the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex will be further tested in an assay of insulin stimulated glucose uptake in differentiated L6-K1 cells or other skeletal muscle cells, muscle tissue biopsies, adipocytes or adipocyte cell lines. An active compound should stimulate basal and insulin stimulated glucose uptake in a manner similar to the NAD(P)H oxidase inhibitor diphenylene iodonium (DPI). The compounds will preferably be of such nature that they are suited for oral administration, but any route of administration, such as, intravenous, suppository or parental routes will be considered.

10

15

20

25

30

In yet another aspect, the invention provides the use of an NAD(P)H oxidase- or NAD(P)H oxidase complex inhibitor or antagonist, as described above, in the manufacture of a medicament for the treatment and/or prevention of a medical condition connected with elevated levels of blood glucose.

As defined herein, the term "prevent" or "treat" is not intended to exclusively mean the complete abolishment of the disease or condition, but is meant that there is complete or some amelioration, so that an improvement over the expected symptomology is clinically observed. An example of one such criterion could be the lowering of blood glucose levels by more than 25%. Other such criteria, well known in the art, could be envisioned.

As defined herein, the term "reactive oxygen species" means compounds selected from the group comprising compounds or compound species such as H_2O_2 , OH and O_2 . Compounds such as these will be referred to as "ROS".

As defined herein, the term "NAD(P)H oxidase" or "NAD(P)H oxidase complex" means one of the proteins or any combination of two or more of the proteins selected from the group comprising the membrane bound cytochrome b558 consisting of gp91^{phox} (nucleotide sequence according to SEQ ID NO:1, amino acid sequence according to SEQ ID NO:2), p22^{phox} (nucleotide sequence according to SEQ ID NO:3, amino acid sequence according to SEQ ID NO:4), Mox2 (nucleotide sequence

according to SEQ ID NO:5, amino acid sequence according to SEQ ID NO:6), Nox4 (nucleotide sequence according to SEQ ID NO:7, amino acid sequence according to SEQ ID NO:8), Nox5 (nucleotide sequence according to SEQ ID NO:9, amino acid sequence according to SEQ ID NO:10), DUOX1 (nucleotide sequence according to SEQ ID NO:11, amino acid sequence according to SEQ ID NO:12), p138Tox (DUOX2) (nucleotide sequence according to SEQ ID NO:13, amino acid sequence according to SEQ ID NO:14), (b5+b5R) oxidoreductase (nucleotide sequence according to SEQ ID NO:15, amino acid sequence according to SEQ ID NO:16), and the cytosolic proteins, p47^{phox} (nucleotide sequence according to SEQ ID NO:17, amino acid sequence according to SEQ ID NO:18), p67 phox (nucleotide sequence according to SEQ ID NO:19, amino acid sequence according to SEQ ID NO:20), p40 phox (nucleotide sequence according to SEQ ID NO:21, amino acid sequence according to SEQ ID NO:22), and a small GTP-binding protein, Rac-1, (which has two different amino acid variants), (nucleotide sequence according to SEQ ID NO:23, amino acid sequence according to SEQ ID NO:24 and SEQ ID NO:25, respectively), or Rac-2, (nucleotide sequence according to SEQ ID NO:26, amino acid sequence according to SEQ ID NO:27), which combination gives rise to reactive oxygen species, or other proteins or assemblies of proteins which essentially have NAD(P)H oxidase activity. Preferably, these enzymes contain consensus sequences for FAD- and/or NAD(P)H-binding sites.

5

10

15

20

25

30

In addition to the specific NAD(P)H oxidase amino acid and nucleotide sequences described herein, fragments or variants thereof that retain NAD(P)H oxidase activity (or fragments or variants thereof that encode polypeptides that retain such activity) can be used in the methods of the invention (e.g., screening methods).

In some embodiments, a polypeptide used in a method of the invention differs from an NAD(P)H oxidase amino acid sequence described herein at one or more residues and yet retains NAD(P)H oxidase activity. The differences are, preferably, differences or changes at a non-essential residue or a conservative substitution. In one embodiment, a polypeptide includes an amino acid sequence that is at least about 60% identical to an NAD(P)H oxidase amino acid sequence described herein or a fragment thereof. Preferably, the polypeptide is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more identical to an NAD(P)H oxidase amino acid sequence described herein. Preferred polypeptide fragments are at least 10%, preferably at least 20%, 30%, 40%, 50%, 60%, 70%, or more, of the length of an NAD(P)H oxidase amino acid sequence described herein.

15

20

25

30

As used herein, "% identity" of two amino acid sequences, or of two nucleic acid sequences, is determined using the algorithm of Karlin and Altschul (PNAS USA 87:2264-2268, 1990), modified as in Karlin and Altschul, PNAS USA 90:5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (J. Mol. Biol. 215:403-410, 1990). BLAST nucleotide searches are performed with the NBLAST program, score = 100, wordlength = 12. BLAST protein searches are performed with the XBLAST program, score = 50, wordlength=3. To obtain gapped alignment for comparison purposes GappedBLAST is utilized as described in Altschul et al (Nucleic Acids Res. 25:3389-3402, 1997). When utilizing BLAST and GappedBLAST programs the default parameters of the respective programs (e.g., XBLAST and NBLAST) are used to obtain nucleotide sequences homologous to a nucleic acid molecule described herein.

PCT/SE03/00618

The term "NAD(P)H oxidase activity", as described herein, refers to enzymatic activity of either the NAD(P)H oxidase or the NAD(P)H oxidase complex, as defined herein, whereby reactive oxygen species (ROS) are produced. Such enzymatic activity is readily established and procedures for this are well known to a skilled person. This activity is well known in the art and methods whereby this can be monitored are well known.

The term "inhibiting" with regards to ROS generating activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex is meant the lowering of said activity to the range between 20%-100% of normal activity when measured with said methods. A preferred value of the inhibitory constant K_i is <10 μ M, or more preferably <1 μ M.

As defined herein, the term "NAD(P)H oxidase inhibitor" means any compound capable of lowering the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex, according to the above mentioned definition.

When activated, the NAD(P)H oxidase complex assembles at the plasma membrane and catalyses the single electron reduction of molecular O₂ to superoxide (O₂⁻). In the presence of superoxide dismutase, O₂⁻ dismutates to hydrogen peroxide (H₂O₂) that can be converted to a hydroxyl radical (OH⁻) in the presence of ferrous ions. The list of other free radicals originating from O₂⁻ that can be formed in the cell is longer, and will not be further discussed here. Several proteins are required for the formation of an active NAD(P)H oxidase complex and may include: p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, Rac-2 [Lambeth et al. (2000) Trends Biochem. Sci. 25: 459-461].

A fully active complex producing oxygen radicals in the presence of NAD(P)H, FAD, GTP and amphiphilic compounds can be reconstituted *in vitro* with individual recombinant proteins [Rotrosen et al., Journal of Biological Chemistry, 268:14256-60 (1993)].

PCT/SE03/00618

The invention will now be demonstrated by the following examples. These examples are for the purpose of illustration only and are not intended to limit the scope of the invention in any way. The information necessary for carrying out these experiments is supplied in the references. Any variations and adjustments that need to be made for correct function of these assays (variations in pH, concentration ranges, etc) will be apparent for a skilled person.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Suitable methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

20

25

30

5

10

15

EXAMPLES

EXAMPLE 1: The NAD(P)H oxidase inhibitor DPI increases glucose uptake in rat skeletal muscle cells

Cell culture medium, fetal bovine serum, antibiotics, trypsin-EDTA were purchased from Life Technologies. Diphenylene iodonium (DPI), cytidine, bovine insulin, bovine serum albumin, and glucose oxidase were purchased from Sigma. 2-Deoxy-[³H] glucose (specific activity 1102.6 GBq/mmol) was purchased from NEN Life Science Products and 2-Deoxy-[¹⁴C] glucose from Amersham Pharmacia Biotech. Tissue culture plastics were purchased from Becton Dickinson.

Rat skeletal muscle L6-K cells were grown in minimal essential medium (α-MEM Glutamax I) containing 10% fetal bovine serum at 37°C, 5% CO₂. The cells were passaged twice weekly by treatment with trypsin-EDTA and transfer of 1/3 of the cells to new flasks with fresh culture medium. For differentiation into myotubes, 30,000 cells

were seeded in 1 ml in 24-well plates. When the cells were confluent, usually after 3 days, the medium was replaced by differentiation medium consisting of α -MEM, 2% fetal bovine serum and penicillin/streptomycin at a concentration of 100 U/ml and 100 μ g/ml, respectively. The medium was replaced every 2-3 days. Between days 4-7, differentiation medium containing 1 mM cytidine was used. The cells were differentiated for 8-10 days before being used in experiments.

On the day before the glucose transport assay, the wells of the culture plate were emptied and 1 ml serum free DMEM containing 5 mM glucose and penicillin/ streptomycin was added. In some experiments the cells were treated over night with test compounds in 1 ml and additional treatments were added the next day to give a total volume of 2 ml. In these experiments, insulin (100-1000 nM) was added in 0.2 ml. When all treatments were performed after 20-24 h in serum free medium, a total volume of 1 ml was used. The wells were emptied and 0.5 ml prewarmed PBS without Ca²⁺/Mg²⁺ containing 1 µCi/ml radioactive 2-deoxy-glucose added. After 10 min at 37°C, the wells were emptied and washed three times with cold PBS. The cell monolayer was solubilized in 0.5 ml 0.5 M NaOH for 3 h at room temperature. 400 µl was mixed with 8 ml scintillation fluid (Optiphase, Wallac) and counted in a scintillation counter (Packard TriCarb). Two 10-µl aliquots were used for determination of protein concentration using the method according to Bradford (Anal. Biochem., 1976, 72:248-54) from BioRad.

10

15

20

25

30

When differentiated L6 cells are incubated with the NAD(P)H oxidase inhibitor DPI [O'Donnell V.B. et al. (1993) Biochem. J. 290: 41-49] a significant increase in glucose uptake can be observed (Fig. 1). This increase is comparable to or greater than that caused by insulin. This effect is seen when cells are stimulated with 0.1-10 µM DPI for 1 h. A bell-shaped dose response curve for DPI with an optimum at 1 µM is recorded. The effect of suboptimal concentrations of DPI during a 1 h treatment could be stimulated further if insulin is added 30 min after DPI. However, insulin has little additional effect when the maximum effect of DPI is reached in the 1 h protocol (Fig. 1). The effective concentrations at which DPI stimulates glucose transport corresponds well to the concentrations inhibiting NAD(P)H oxidase activity in cell free systems [O'Donnell et al., Biochemical Journal, 290:41-9 (1993)]. These results suggest that DPI stimulates glucose transport via activation of the same mechanism as insulin. On the basis of the above results it is postulated that DPI enhances a constitutive activity of the insulin receptor and/or the intracellular insulin-signaling pathway. The existence of such

10

15

20

25

30

a constitutive activity is suggested from experiments in which adipocytes have been transfected with the tyrosine phosphatase PTP1B [Chen et al., Journal of Biological Chemistry, 272:8026-31 (1997)]. These data are compatible with DPI augmenting constitutive intracellular signaling via the same pathway that is used by insulin.

13

PCT/SE03/00618

EXAMPLE 2: Glucose oxidase reduces the effect of DPI on glucose uptake

Assuming that the enhancing effect of DPI on insulin signaling was due to inhibition of ROS production, it was investigated whether an exogenous source of H_2O_2 could counteract the effect of DPI. To this end, L6 cells were treated with 25 mU/ml of glucose oxidase for 30 min before addition of DPI. Such a treatment has previously been shown to result in a steady production of micromolar concentrations of H_2O_2 that can freely pass the cell membrane and cause inhibition of insulin signaling [Tirosh, Potashnik et al., Journal of Biological Chemistry, 274:10595-602 (1999)].

It was found that glucose oxidase reduced the stimulatory effect of DPI by 68% and insulin stimulated glucose transport by 65% (Fig. 2). The available results suggest that H_2O_2 can counteract the effect of DPI in addition to inducing insulin resistance. This further strengthens the similarity between the effects of insulin and DPI and shows that DPI acts by inhibiting H_2O_2 production. In spite of superoxide being the primary product of NAD(P)H oxidase, H_2O_2 is the main effector in the cell since superoxide is converted to H_2O_2 by superoxide dismutase.

EXAMPLE 3: DPI decreases blood glucose levels in ob/ob mice

Studies were conducted *in vivo*, in an animal model of obesity characterized by insulin resistance. Eight-month old C57BL/6J ob/ob mice (M&B A/S, Denmark) were matched for sex, weight and fasting blood glucose concentrations. The animals were injected intraperitoneally once daily with DPI (1 mg/kg) or water for 4 days. On day 5, the animals were fasted for 2.5 h and then given an i.p. injection of human insulin 0.5 U/kg (Actrapid, Novo Nordisk, Denmark) and their blood glucose levels were monitored for 4 h by sampling from the tail. The glucose concentration was determined using a Glucometer Accutrend Sensor (Roche).

Without any overt side effects of the DPI treatment, the treated animals exhibited significantly lower blood glucose levels than the control group 1-4 h after injection of insulin, suggesting a decreased insulin resistance (Fig. 3).

15

25

30

EXAMPLE 4: Identification of agents inhibiting NAD(P)H oxidase

Methods to be used for identifying compounds that inhibit the activity of the NAD(P)H oxidase complex are illustrated.

- (A) Neutrophil membrane and cytosol assay for superoxide mediated
 cytochrome c reduction (Diatchuk, V. et al. (1997) J. Biol. Chem. 272: 13292-13301).
 Sources of neutrophil membranes and cytosol from buffy coats of normal donors are obtainable from the Blood Bank. Enzyme cofactors and cytochrome c for detection of superoxide-mediated reduction are commercially available. The assay is based on a color change that occurs upon reduction of cytochrome c. This change can be measured
 as a change in light absorbance using a standard microplate spectrophotometer.
 - (B) Neutrophil membrane + recombinant p47^{phox}, p67^{phox} and rac1 for superoxide-mediated cytochrome c reduction (absorbance) (Nisimoto, Y. et al. (1997) J. Biol. Chem. 272: 18834-18841).
 - (C) Fully recombinant NAD(P)H oxidase assay for superoxide mediated cytochrome c reduction [Rotrosen, D. et al, (1993) J. Biol. Chem. 268: 14256-14260].
 - (D) Fluorescence assay, which measures the interaction between rac and p67^{phox} [Nisimoto, Y. et al. (1997) J. Biol. Chem. 272: 18834-18841]. This assay would limit the screening to detection of compounds interfering with this particular step in the activation of the oxidase. The fluorescent GTP analog 2'-(or-3')-O-(N-
- methylanthraniloyl) -βγ-imidoguanosine 5'-triphosphate (MANT-GMPPNP, available from Molecular Probes), binds tightly to Rac, and shows an increase in fluorescence when p67^{phox} is added, indicating complex formation. Rac1 and Rac2 bind to p67^{phox} with a 1:1 stoichiometry and with Kd values of 120 nM and 60 nM, respectively.
 - (E) Binding assay utilizing ¹²⁵I- or fluorescence labeled mastoparan. Mastoparan is a peptide present in wasp venom that has been shown to inhibit NAD(P)H oxidase activation, most likely via its ability to bind to p67^{phox} [Tisch-Idelson, D., et al.(2001) Biochemical Pharmacology 61: 1063-1071].
 - (F) Test compounds can be analyzed in a nitroblue tetrazolium reduction assay utilizing a thioredoxin-gp91^{phox} fusion protein. This protein has weak diaphorase activity in the presence of NAD(P)H and FAD and is inhibited by DPI.
 - (G) Test compounds can be added in appropriate amounts to cultured cells. The reactive oxygen species released from said cells may be measured with the use of a probe, resorufin, which becomes fluorescent in the presence of hydrogen peroxide and a peroxidase [Zhou, M. et al., (1997) Anal. Biochem., 253: 162-168].

WO 03/087399 PCT/SE03/00618

Intracellular production of ROS can be measured with the use of various cell permeable analogs of dichlorofluorescin acetate as described by Xie, J.I. et al.[(1999) J. Biol. Chem. 274: 19323-19328].

5

CLAIMS

15

20

25

- 1. A method for identifying an agent that increases glucose uptake by a cell, the method comprising:
- contacting a cell with a candidate agent that inhibits the activity of an NAD(P)H oxidase or an NAD(P)H oxidase complex;

measuring glucose uptake by the cell in the presence of the candidate agent; and determining whether the candidate agent increases glucose uptake by the cell.

- 2. The method of claim 1, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.
 - 3. The method of claim 1, wherein the cell is a muscle cell.
 - 4. The method of claim 1, wherein the cell is an adipocyte.
 - 5. The method of claim 1, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.
 - 6. The method of claim 1, wherein the candidate agent is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.
 - 7. The method of claim 1, further comprising comparing glucose uptake by the cell in the presence of the candidate agent with glucose uptake by a cell in the absence of the candidate agent.
- 8. The method of claim 1, further comprising contacting the candidate agent with the NAD(P)H oxidase or the NAD(P)H oxidase complex and determining that the candidate agent inhibits the activity of the NAD(P)H oxidase or the NAD(P)H oxidase complex.

- 9. A method for increasing glucose uptake in a cell, the method comprising contacting a cell with an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to increase glucose uptake by the cell.
- 10. The method of claim 9, further comprising detecting an increase in glucose uptake by the cell in response to the contacting of the cell with the inhibitor.
 - 11. The method of claim 9, wherein the cell is a muscle cell.
- 10 12. The method of claim 9, wherein the cell is an adipocyte.

15

25

30

- 13. The method of claim 9, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.
- 14. The method of claim 9, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.
- 15. The method of claim 9, wherein the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.
 - 16. A method for the treatment of a medical condition, the method comprising: selecting an individual diagnosed as having a medical condition characterized by elevated levels of blood glucose; and

administering to the individual an amount of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex effective to reduce blood glucose levels in the individual.

17. The method of claim 16, further comprising detecting a reduction in blood glucose levels in the individual in response to the administration of the inhibitor.

- 18. The method of claim 16, wherein the medical condition is characterized by insulin resistance.
- 19. The method of claim 16, wherein the medical condition is characterized by a need for increased activity of the insulin receptor.
 - 20. The method of claim 16, wherein the medical condition is characterized by a need for increased activity of the intracellular insulin-signaling pathway.
- 10 21. The method of claim 16, wherein the medical condition is diabetes.
 - 22. The method of claim 21, wherein the medical condition is type II diabetes.
- 23. The method of claim 16, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is selected from the group consisting of gp91phox, p22phox, Mox2, Nox4, Nox5, DUOX1, DUOX2, (b5+b5R) oxidoreductase, p47phox, p67phox, p40phox, Rac-1, and Rac-2.
 - 24. The method of claim 16, wherein the NAD(P)H oxidase or the NAD(P)H oxidase complex is a human NAD(P)H oxidase or a human NAD(P)H oxidase complex.

25

25. The method of claim 16, wherein the inhibitor is selected from the group consisting of pyridine, imidazole, diethyl pyrocarbonate, chloromercuribenzoic acid, 4-(2-aminomethyl)-sulfonyl fluoride acetovanillone, and derivatives thereof.

26. Use of an inhibitor of an NAD(P)H oxidase or an NAD(P)H oxidase complex, effective to increase glucose uptake by the cell, in the manufacture of a medicament for increasing glucose uptake in a cell.

Fig. 1




Fig. 2





Fig. 3



SEQUENCE LISTING

<110> Biovitrum AB

<120> New use

<130> BV-1000

<160> 27

<170> PatentIn version 3.1

<210> 1

<211> 4266

<212> DNA

<213> Homo sapiens

<400> 1 cttcctctgc caccatgggg aactgggctg tgaatgaggg gctctccatt tttgtcattc 60 tggtttggct ggggttgaac gtcttcctct ttgtctggta ttaccgggtt tatgatattc 120 cacctaagtt cttttacaca agaaaacttc ttgggtcagc actggcactg gccagggccc 180 ctgcagcctg cctgaatttc aactgcatgc tgattctctt gccagtctgt cgaaatctgc 240 tgtccttcct caggggttcc agtgcgtgct gctcaacaag agttcgaaga caactggaca 300 ggaateteac ettteataaa atggtggeat ggatgattge aetteaetet gegatteaea 360 ccattgcaca tctatttaat gtggaatggt gtgtgaatgc ccgagtcaat aattctgatc 420 cttattcagt agcactctct gaacttggag acaggcaaaa tgaaagttat ctcaattttg 480 ctcgaaagag aataaagaac cctgaaggag gcctgtacct ggctgtgacc ctgttggcag 540 gcatcactgg agttgtcatc acgctgtgcc tcatattaat tatcacttcc tccaccaaaa 600 ccatccggag gtcttacttt gaagtctttt ggtacacaca tcatctcttt gtgatcttct 660 tcattggcct tgccatccat ggagctgaac gaattgtacg tgggcagacc gcagagagtt 720 tggctgtgca taatataaca gtttgtgaac aaaaaatctc agaatgggga aaaataaagg 780 aatgcccaat ccctcagttt gctggaaacc ctcctatgac ttggaaatgg atagtgggtc 840 ccatgtttct gtatctctgt gagaggttgg tgcggttttg gcgatctcaa cagaaggtgg 900 tcatcaccaa ggtggtcact caccetttca aaaccatcga gctacagatg aagaagaagg 960 ggttcaaaat ggaagtggga caatacattt ttgtcaagtg cccaaaggtg tccaagctgg 1020 agtggcaccc ttttacactg acatccgccc ctgaggaaga cttctttagt atccatatcc 1080 gcatcgttgg ggactggaca gaggggctgt tcaatgcttg tggctgtgat aagcaggagt 1140 ttcaagatgc gtggaaacta cctaagatag cggttgatgg gccctttggc actgccagtg 1200 aagatgtgtt cagctatgag gtggtgatgt tagtgggagc agggattggg gtcacaccct 1260

PCT/SE03/00618

tegeatecat teteaagtea gtetggtaca aatattgeaa taaegeeace aatetgaage 1320 tcaaaaagat ctacttctac tggctgtgcc gggacacaca tgcctttgag tggtttgcag 1380 1440 acaacatcta cctcactggc tgggatgagt ctcaggccaa tcactttgct gtgcaccatg 1500 atgaggagaa agatgtgatc acaggcctga aacaaaagac tttgtatgga cggcccaact 1560 gggataatga attcaagaca attgcaagtc aacaccctaa taccagaata ggagttttcc 1620 totgtggacc tgaagccttg gctgaaaccc tgagtaaaca aagcatctcc aactctgagt 1680 ctggccctcg gggagtgcat ttcattttca acaaggaaaa cttctaactt gtctcttcca 1740 tgaggaaata aatgtgggtt gtgctgccaa atgctcaaat aatgctaatt gataatataa 1800 atacccctg cttaaaaatg gacaaaaaga aactataatg taatggtttt cccttaaagg 1860 aatgtcaaag attgtttgat agtgataagt tacatttatg tggagctcta tggttttgag 1920 agcactttta caaacattat ttcatttttt tcctctcagt aatgtcagtg gaagttaggg 1980 aaaagattot tggactcaat tttagaatca aaagggaaag gatcaaaagg ttcagtaact 2040 tccctaagat tatgaaactg tgaccagatc tagcccatct tactccaggt ttgatactct 2100 ttccacaata ctgagctgcc tcagaatcct caaaatcagt ttttatattc cccaaaagaa 2160 gaaggaaacc aaggagtagc tatatatttc tactttgtgt catttttgcc atcattatta 2220 tcatactgaa ggaaattttc cagatcatta ggacataata catgttgaga gtgtctcaac 2280 acttattagt gacagtattg acatctgagc atactccagt ttactaatac agcagggtaa 2340 ctgggccaga tgttctttct acagaagaat attggattga ttggagttaa tgtaatactc 2400 atcatttacc actgtgcttg gcagagagcg gatactcaag taagttttgt taaatgaatg 2460 aatgaattta gaaccacaca atgccaagat agaattaatt taaagcctta aacaaaattt 2520 atctaaagaa ataacttcta ttactgtcat agaccaaagg aatctgattc tccctagggt 2580 caagaacagg ctaaggatac taaccaatag gattgcctga agggttctgc acattcttat 2640 ttgaagcatg aaaaaagagg gttggaggtg gagaattaac ctcctgccat gactctggct 2700 catctagtcc tgctccttgt gctataaaat aaatgcagac taatttcctg cccaaagtgg 2760 tetteteeag etageeetta tgaatattga aettaggaat tgtgacaaat atgtatetga 2820 tatggtcatt tgttttaaat aacacccacc ccttattttc cgtaaataca cacacaaaat 2880 ggatcgcatc tgtgtgacta atggtttatt tgtattatat catcatcatc atcctaaaat 2940 taacaaccca gaaacaaaaa tctctataca gagatcaaat tcacactcaa tagtatgttc 3000 tgaatatatg ttcaagagag agtctctaaa tcactgttag tgtggccaag agcagggttt 3060

, : : !

17.6

3/61 tctttttgtt cttagaactg ctcccatttc tgggaactaa aaccagtttt atttgcccca 3120 ccccttggag ccacaaatgt ttagaactct tcaacttcgg taatgaggaa gaaggagaaa 3180 gagctggggg aagggcagaa gactggttta ggaggaaaag gaaataagga gaaaagagaa 3240 tgggagagtg agagaaaata aaaaaggcaa aagggagaga gaggggaagg gggtctcata 3300 ttggtcattc cctgccccag atttcttaaa gtttgatatg tatagaatat aattgaaqqa 3360 ggtatacaca tactgatgtt gttttgatta tctatggtat tgaatctttt aaaatctggt 3420 cacaaatttt gatgctgagg gggattattc aagggactag gatgaactaa ataagaactc 3480 agttgttctt tgtcatacta ctattccttt cgtctcccag aatcctcagg gcactgaggg 3540 taggtctgac aaataaggcc tgctgtgcga atatagcctt tctgaaatgt accaggatgg 3600 tttetgetta gagacaetta ggtecageet gtteacaetg caecteaggt atcaatteat 3660 ctattcaaca gatatttatt gtgttattac tatgagtcag gctctgttta ttgtttcaat 3720 tctttacacc aaagtatgaa ctggagaggg tacctcagtt ataaggagtc tgagaatatt 3780 ggccctttct aacctatgtg cataattaaa accagcttca tttgttgctc cgagagtgtt 3840 tctccaaggt tttctatctt caaaaccaac taagttatga aagtagagag atctgccctg 3900 tgttatccag ttatgagata aaaaatgaat ataagagtgc ttgtcattat aaaagtttcc 3960 tttttatctc tcaagccacc agctgccagc caccacgagc cagctgccag cctagctttt 4020 ttttttttt ttttttagc acttagtatt tagcatttat taacaggtac tctaagaatg 4080 atgaagcatt gtttttaatc ttaagactat gaaggttttt cttagttctt ctgcttttgc 4140 aattgtgttt gtgaaatttg aatacttgca ggctttgtat gtgaataatt ctagcggggg 4200 acctgggaga taattctacg gggaattctt aaaactgtgc tcaactatta aaatgaatga 4260 gctttc

4266

<210> <211> 570

<213> Homo sapiens

<400> 2

Met Gly Asn Trp Ala Val Asn Glu Gly Leu Ser Ile Phe Val Ile Leu

Val Trp Leu Gly Leu Asn Val Phe Leu Phe Val Trp Tyr Tyr Arg Val

Tyr Asp Ile Pro Pro Lys Phe Phe Tyr Thr Arg Lys Leu Leu Gly Ser

Ala Leu Ala Leu Ala Arg Ala Pro Ala Ala Cys Leu Asn Phe Asn Cys

WO 03/087399 PCT/SE03/00618

Met Leu Ile Leu Leu Pro Val Cys Arg Asn Leu Leu Ser Phe Leu Arg 65 70 75 80

Gly Ser Ser Ala Cys Cys Ser Thr Arg Val Arg Arg Gln Leu Asp Arg 85 90 95

Asn Leu Thr Phe His Lys Met Val Ala Trp Met Ile Ala Leu His Ser

Ala Ile His Thr Ile Ala His Leu Phe Asn Val Glu Trp Cys Val Asn 115 120 125

Ala Arg Val Asn Asn Ser Asp Pro Tyr Ser Val Ala Leu Ser Glu Leu 130 135 140

Gly Asp Arg Gln Asn Glu Ser Tyr Leu Asn Phe Ala Arg Lys Arg Ile 145 150 155 160

Lys Asn Pro Glu Gly Gly Leu Tyr Leu Ala Val Thr Leu Leu Ala Gly 165 170 175

Ile Thr Gly Val Val Ile Thr Leu Cys Leu Ile Leu Ile Ile Thr Ser

Ser Thr Lys Thr Ile Arg Arg Ser Tyr Phe Glu Val Phe Trp Tyr Thr 195 200 205

His His Leu Phe Val Ile Phe Phe Ile Gly Leu Ala Ile His Gly Ala 210 215 220

Glu Arg Ile Val Arg Gly Gln Thr Ala Glu Ser Leu Ala Val His Asn 225 230 235 240

Ile Thr Val Cys Glu Gln Lys Ile Ser Glu Trp Gly Lys Ile Lys Glu 245 250 255

Cys Pro Ile Pro Gln Phe Ala Gly Asn Pro Pro Met Thr Trp Lys Trp 260 265 270

Ile Val Gly Pro Met Phe Leu Tyr Leu Cys Glu Arg Leu Val Arg Phe 275 280 285

Trp Arg Ser Gln Gln Lys Val Val Ile Thr Lys Val Val Thr His Pro
290 295 300

Phe Lys Thr Ile Glu Leu Gln Met Lys Lys Gly Phe Lys Met Glu 305 310 315 320

Val Gly Gln Tyr Ile Phe Val Lys Cys Pro Lys Val Ser Lys Leu Glu

Trp His Pro Phe Thr Leu Thr Ser Ala Pro Glu Glu Asp Phe Phe Ser 340 345 350

Ile His Ile Arg Ile Val Gly Asp Trp Thr Glu Gly Leu Phe Asn Ala 355 360 365

Cys Gly Cys Asp Lys Gln Glu Phe Gln Asp Ala Trp Lys Leu Pro Lys 370 375 380

~ ~		-								61					
385	Ala	. vai	Asp	Gly	390	Phe	: Gly	Thr	Ala	Ser 395	Glu	Asp	Val	Phe	Se 40
Tyr	Glu	Val	Val	Met 405	Leu	val	. Gly	Ala	Gly 410		Gly	Val	Thr	Pro 415	Ph
Ala	Ser	Ile	Leu 420	Ьys	Ser	Val	Trp	Tyr 425	Lys	Tyr	Сув	Asn	Asn 430	Ala	Th
Asn	Leu	Lys 435	Leu	Lys	Lys	Ile	Tyr 440	Phe	Tyr	Trp	Leu	Cys 445	Arg	Asp	Th
His	Ala 450	Phe	Glu	Trp	Phe	Ala 455	Asp	Leu	Leu	Gln	Leu 460	Leu	Glu	Ser	Gl
Met 465	Gln	Glu	Arg	Asn	Asn 470	Ala	Gly	Phe	Leu	Ser 475	Tyr	Asn	Ile	Tyr	Le:
Thr	Gly	Trp	Asp	Glu 485	Ser	Gln	Ala	Asn	His 490	Phe	Ala	Val	His	His 495	Ası
Glu	Glu	Lys	Asp 500	Val	Ile	Thr	Gly	Leu 505	Lys	Gln	Lys	Thr	Leu 510	Tyr	Gl
Arg	Pro	Asn 515	Trp	Asp	Asn	Glu	Phe 520	Lys	Thr	Ile	Ala	Ser 525	Gln	His	Pro
Asn	Thr 530	Arg	Ile	Gly	Val	Phe 535	Leu	Cys	Gly	Pro	Glu 540	Ala	Leu	Ala	Glu
Thr 545	Leu	Ser	Lys	Gln	Ser 550	Ile	Ser	Asn		Glu 555	Ser	Gly	Pro		Gly 560
/al	His	Phe	Ile	Phe 565	Asn	Lys .	Glu	Asn	Phe 570						
		•													

<210> 687 <212> DNA <213> Homo sapiens

<400> 3 gcagtgtccc agccgggttc gtgtcgccat ggggcagatc gagtgggcca tgtgggccaa 60 cgagcaggcg ctggcgtccg gcctgatcct catcaccggg ggcatcgtgg ccacagctgg 120 gcgcttcacc cagtggtact ttggtgccta ctccattgtg gcgggcgtgt ttgtgtgcct 180 gctggagtac ccccggggga agaggaagaa gggctccacc atggagcgct ggggacagaa 240 gcacatgacc gccgtggtga agctgttcgg gccctttacc aggaattact atgttcgggc 300 cgtcctgcat ctcctgctct cggtgcccgc cggcttcctg ctggccacca tccttgggac 360 cgcctgcctg gccattgcga gcggcatcta cctactggcg gctgtgcgtg gcgagcagtg 420 gacgcccatc gagcccaagc cccgggagcg gccgcagatc ggaggcacca tcaagcagcc 480 gcccagcaac ccccgccgc ggcccccggc cgaggcccgc aagaagccca gcgaggagga 540

ggctgcggcg gcggcgggg gacccccggg aggtccccag gtcaacccca tcccggtgac 600 cgacgaggtc gtgtgacctc gccccggacc tgccctcca ccaggtgcac ccacctgcaa 660 taaacgcagc gaaggccggg aaaaaaaa 660

<210> 4

<211> 195

<212> PRT

<213> Homo sapiens

<400> 4

Met Gly Gln Ile Glu Trp Ala Met Trp Ala Asn Glu Gln Ala Leu Ala 1 5 10 15

Ser Gly Leu Ile Leu Ile Thr Gly Gly Ile Val Ala Thr Ala Gly Arg
20 25 30

Phe Thr Gln Trp Tyr Phe Gly Ala Tyr Ser Ile Val Ala Gly Val Phe 35 40 45

Val Cys Leu Leu Glu Tyr Pro Arg Gly Lys Arg Lys Lys Gly Ser Thr 50 55 60

Met Glu Arg Trp Gly Gln Lys His Met Thr Ala Val Val Lys Leu Phe 70 75 80

Gly Pro Phe Thr Arg Asn Tyr Tyr Val Arg Ala Val Leu His Leu Leu 85 90 95

Leu Ser Val Pro Ala Gly Phe Leu Leu Ala Thr Ile Leu Gly Thr Ala
100 105 110

Cys Leu Ala Ile Ala Ser Gly Ile Tyr Leu Leu Ala Ala Val Arg Gly 115 120 125

Glu Gln Trp Thr Pro Ile Glu Pro Lys Pro Arg Glu Arg Pro Gln Ile 130 135 140

Gly Gly Thr Ile Lys Gln Pro Pro Ser Asn Pro Pro Pro Arg Pro Pro 145 150 155 160

Ala Glu Ala Arg Lys Lys Pro Ser Glu Glu Glu Ala Ala Ala Ala Ala Ala 165 170 175

Gly Gly Pro Pro Gly Gly Pro Gln Val Asn Pro Ile Pro Val Thr Asp 180 185 190

Glu Val Val 195

<210> 5

<211> 2044

<212> DNA

<213> Homo sapiens

<400> 5

caaagacaaa ataatttact agggaagccc ttactaacga cccaacatcc agacacaggt

gagettetag aetttggagg teaagteeag geattgtgtt tteaateaag ttattgatte

caaagaactc caccaggaat tcctgtgacg gcctgttgat atgagctccc agttgggaac

1860

1920

2040

2044

	8/61											
tggtgaa	taa taa	attaact	a ttgt	gaac	ag ta	acaci	tata	c ca	tact	tcct	tag	cttataa
ataacat	gtc ata	tacaad	a gaac	aaaa	ac at	tta	ctga	a at	taaa	atat	att	atgtttc
tcca												
<211> <212>	6 568 PRT Homo sa	piens										
<400> Met Met	6 Gly Cy	s Trp 5	Ile Lei	ı Asn	ı Glu	Gly 10	. Leu	ı Sei	r Thi	r Ile	Leu 15	ı Val
Leu Ser	Trp Le	u Gly	Ile Ası	ı Phe	Tyr 25	Leu	Phe	: Ile	e Asp	Thr 30	Phe	e Tyr
Trp Tyr	Glu Gl 35	u Glu	Glu Ser	Phe 40	His	Tyr	Thr	Arg	Val 45	. Ile	: Leu	Gly
Ser Thr 50	Leu Al	a Trp	Ala Arg 55	, Ala	Ser	Ala	Leu	Сув 60	Leu	Asn	Phe	Asn
Cys Met 65	Leu Ile	e Leu	Ile Pro 70	Val	Ser	Arg	Asn 75	Leu	Ile	Ser	Phe	Ile 80
Arg Gly	Thr Se	r Ile (85	Cys Cys	Arg	Gly	Pro 90	Trp	Arg	Arg	Gln	Leu 95	Asp
Lys Asn	Leu Arç	g Phe I	His Lys	Leu	Val 105	Ala	Tyr	Gly	Ile	Ala 110	Val	Asn
	,			120					125			
Trp Ser			135					140				
Leu Gly 1 145			.50				155					160
Pro Thr		165				170					175	
Gly Leu v	180				185					190		
Glu Phe 1	le Arg 195	Gln A	la Ser	Tyr 200	Glu	Leu	Phe	Trp	Tyr 205	Thr	His	His
Val Phe 1 210	le Val	Phe P	he Leu 215	Ser	Leu ,	Ala	Ile	His 220	Gly	Thr	Gly	Arg
Ile Val A 225		2.	3 0				235					240
Phe Cys A	rg Asp	Arg Ty 245	yr Ala	Glu '	Trp (3ln (250	Thr	Val .	Ala		Cys 255	Pro

- Val Pro Gln Phe Ser Gly Lys Glu Pro Ser Ala Trp Lys Trp Ile Leu 260 265 270
- Gly Pro Val Val Leu Tyr Ala Cys Glu Arg Île Île Arg Phe Trp Arg 275 280 285
- Phe Gln Gln Glu Val Val Ile Thr Lys Val Val Ser His Pro Ser Gly 290 295 300
- Val Leu Glu Leu His Met Lys Lys Arg Gly Phe Lys Met Ala Pro Gly 305 310 315 320
- Gln Tyr Ile Leu Val Gln Cys Pro Ala Ile Ser Ser Leu Glu Trp His
- Pro Phe Thr Leu Thr Ser Ala Pro Gln Glu Asp Phe Phe Ser Val His 340 345 350
- Ile Arg Ala Ala Gly Asp Trp Thr Ala Ala Leu Leu Glu Ala Phe Gly 355 360 365
- Ala Glu Gly Gln Ala Leu Gln Glu Pro Trp Ser Leu Pro Arg Leu Ala 370 375 380
- Val Asp Gly Pro Phe Gly Thr Ala Leu Thr Asp Val Phe His Tyr Pro 385 390 395 400
- Val Cys Val Cys Val Ala Ala Gly Ile Gly Val Thr Pro Phe Ala Ala 405 410 415
- Leu Leu Lys Ser Ile Trp Tyr Lys Cys Ser Glu Ala Gln Thr Pro Leu 420 425 430
- Lys Leu Ser Lys Val Tyr Phe Tyr Trp Ile Cys Arg Asp Ala Arg Ala
 435
 440
 445
- Phe Glu Trp Phe Ala Asp Leu Leu Leu Ser Leu Glu Thr Arg Met Ser 450 460
- Glu Gln Gly Lys Thr His Phe Leu Ser Tyr His Ile Phe Leu Thr Gly
 465 470 475 480
- Trp Asp Glu Asn Gln Ala Leu His Ile Ala Leu His Trp Asp Glu Asn 485 490 495
- Thr Asp Val Ile Thr Gly Leu Lys Gln Lys Thr Phe Tyr Gly Arg Pro 500 505 510
- Asn Trp Asn Asn Glu Phe Lys Gln Ile Ala Tyr Asn His Pro Ser Ser 515 520 525
- Ser Ile Gly Val Phe Phe Cys Gly Pro Lys Ala Leu Ser Arg Thr Leu 530 540
- Gln Lys Met Cys His Leu Tyr Ser Ser Ala Asp Pro Arg Gly Val His 545 550 555 560
- Phe Tyr Tyr Asn Lys Glu Ser Phe 565

<210> 7 <211> 2232 <212> DNA <213> Homo sapiens

<400> 7

÷.

ccgcacaact gtaaccgctg ccccggccgc cgcccgctcc ttctcgggcc ggcgggcaca 60 gagcgcagcg cggcggggcc ggcggcatgg ctgtgtcctg gaggagctgg ctcgccaacg 120 aaggggttaa acacctctgc ctgttcatct ggctctccat gaatgtcctg cttttctgga 180 aaaccttctt gctgtataac caagggccag agtatcacta cctccaccag atgttggggc 240 taggattgtg tctaagcaga gcctcagcat ctgttcttaa cctcaactgc agccttatcc 300 ttttacccat gtgccgaaca ctcttggctt acctccgagg atcacagaag gttccaagca 360 ggagaaccag gagattgttg gataaaagca gaacattcca tattacctgt ggtgttacta 420 totgtatttt ctcaggogtg catgtggctg cccatctggt gaatgccctc aacttctcag 480 tgaattacag tgaagacttt gttgaactga atgcagcaag ataccgagat gaggatccta 540 gaaaacttct cttcacaact gttcctggcc tgacaggggt ctgcatggtg gtggtgctat 600 tecteatgat cacageetet acatatgeaa taagagttte taaetatgat atettetggt 660 atactcataa cetettett gtettetaca tgetgetgae gttgeatgtt teaggaggge 720 tgctgaagta tcaaactaat ttagataccc accctcccgg ctgcatcagt cttaaccgaa 780 ccagctctca gaatatttcc ttaccagagt atttctcaga acattttcat gaacctttcc 840 ctgaaggatt ttcaaaaccg gcagagttta cccagcacaa atttgtgaag atttgtatgg 900 aagageceag attecaaget aatttteeae agaettgget ttggatttet ggaeetttgt 960 gcctgtactg tgccgaaaga ctttacaggt atatccggag caataagcca gtcaccatca 1020 tttcggtcat aagtcatccc tcagatgtca tggaaatccg aatggtcaaa gaaaatttta 1080 aagcaagacc tggtcagtat attactctac attgtcccag tgtatctgca ttagaaaatc 1140 atccatttac cctcacaatg tgtccaactg aaaccaaagc aacatttggg gttcatctta 1200 aaatagtagg agactggaca gaacgatttc gagatttact actgcctcca tctagtcaag 1260 actocgaaat totgocotto attoaatota gaaattatoo caagotgtat attgatggto 1320 cttttggaag tccatttgag gaatcactga actatgaggt cagcctctgc gtggctggag 1380 gcattggagt aactccattt gcatcaatac tcaacaccct gttggatgac tggaaaccat 1440 acaagcttag aagactatac tttatttggg tatgcagaga tatccagtcc ttccgttggt 1500 ttgcagattt actctgtatg ttgcataaca agttttggca agagaacaga cctgactatg 1560 tcaacatcca gctgtacctc agtcaaacag atgggataca gaagataatt ggagaaaaat 1620

			,			
atcatgcact	gaattcaaga	ctgtttatag	gacgtcctcg	gtggaaactt	ttgtttgatg	1680
aaatagcaaa	atataacaga	ggaaaaacag	ttggtgtttt	ctgttgtgga	cccaattcac	1740
tatccaagac	tcttcataaa	ctgagtaacc	agaacaactc	atatgggaca	agatttgaat	1800
acaataaaga	gtctttcagc	tgaaaacttt	tgccatgaag	caggactcta	aagaaggaat	1860
gagtgcaatt	tctaagactt	tgaaactcag	cggaatcaat	cagctgtgtt	atgccaaaga	1920
atagtaaggt	tttcttattt	atgattattt	gaaaatggaa	atgtgagaat	gtggcaacat	1980
gaccgtcaca	ttacatgttt	aatctggaaa	ccaaagagac	cctgaagaat	atttgatgtg	2040
atgattcatt	ttcagttctc	aaattaaaag	aaaactgtta	gatgcacact	gttgattttc	2100
atggtggatt	caagaactcc	ctagtgagga	gctgaacttg	ctcaatctaa	ggctgattgt	2160
cgtgttcctc	tttaaattgt	ttttggttga	acaaatgcaa	gattgaacaa	aattaaaaat	2220
tcattgaagc	tg -					2232

<210> 8

<211> 578

<212> PRT

<213> Homo sapiens

<400> 8

Met Ala Val Ser Trp Arg Ser Trp Leu Ala Asn Glu Gly Val Lys His 1 10 15

Leu Cys Leu Phe Ile Trp Leu Ser Met Asn Val Leu Leu Phe Trp Lys 20 25 30

Thr Phe Leu Leu Tyr Asn Gln Gly Pro Glu Tyr His Tyr Leu His Gln 35 40 45

Met Leu Gly Leu Gly Leu Cys Leu Ser Arg Ala Ser Ala Ser Val Leu 50 55 60

Asn Leu Asn Cys Ser Leu Ile Leu Leu Pro Met Cys Arg Thr Leu Leu 65 70 75 80

Ala Tyr Leu Arg Gly Ser Gln Lys Val Pro Ser Arg Arg Thr Arg Arg
85 90 95

Leu Leu Asp Lys Ser Arg Thr Phe His Ile Thr Cys Gly Val Thr Ile 100 105 110

Cys Ile Phe Ser Gly Val His Val Ala Ala His Leu Val Asn Ala Leu 115 120 125

Asn Phe Ser Val Asn Tyr Ser Glu Asp Phe Val Glu Leu Asn Ala Ala 130 135 140

Arg Tyr Arg Asp Glu Asp Pro Arg Lys Leu Leu Phe Thr Thr Val Pro
145 150 155

Gly Leu Thr Gly Val Cys Met Val Val Val Leu Phe Leu Met Ile Thr 165 170 175

- Ala Ser Thr Tyr Ala Ile Arg Val Ser Asn Tyr Asp Ile Phe Trp Tyr 180 185 190
- Thr His Asn Leu Phe Phe Val Phe Tyr Met Leu Leu Thr Leu His Val
- Ser Gly Gly Leu Leu Lys Tyr Gln Thr Asn Leu Asp Thr His Pro Pro 210 215 220
- Gly Cys Ile Ser Leu Asn Arg Thr Ser Ser Gln Asn Ile Ser Leu Pro 225 230 235 240
- Glu Tyr Phe Ser Glu His Phe His Glu Pro Phe Pro Glu Gly Phe Ser 245 250 255
- Lys Pro Ala Glu Phe Thr Gln His Lys Phe Val Lys Ile Cys Met Glu 260 265 270
- Glu Pro Arg Phe Gln Ala Asn Phe Pro Gln Thr Trp Leu Trp Ile Ser 275 280 285
- Gly Pro Leu Cys Leu Tyr Cys Ala Glu Arg Leu Tyr Arg Tyr Ile Arg 290 295 300
- Ser Asn Lys Pro Val Thr Ile Ile Ser Val Ile Ser His Pro Ser Asp 305 310 315 320
- Val Met Glu Ile Arg Met Val Lys Glu Asn Phe Lys Ala Arg Pro Gly 325 330 335
- Gln Tyr Ile Thr Leu His Cys Pro Ser Val Ser Ala Leu Glu Asn His 340 345 350
- Pro Phe Thr Leu Thr Met Cys Pro Thr Glu Thr Lys Ala Thr Phe Gly 355 360 365
- Val His Leu Lys Ile Val Gly Asp Trp Thr Glu Arg Phe Arg Asp Leu 370 375 380
- Leu Leu Pro Pro Ser Ser Gln Asp Ser Glu Ile Leu Pro Phe Ile Gln 385 390 395 400
- Ser Arg Asn Tyr Pro Lys Leu Tyr Ile Asp Gly Pro Phe Gly Ser Pro 405 410 415
- Phe Glu Glu Ser Leu Asn Tyr Glu Val Ser Leu Cys Val Ala Gly Gly 420 425 430
- Ile Gly Val Thr Pro Phe Ala Ser Ile Leu Asn Thr Leu Leu Asp Asp 435 440 445
- Trp Lys Pro Tyr Lys Leu Arg Arg Leu Tyr Phe Ile Trp Val Cys Arg
 450 455 460
- Asp Ile Gln Ser Phe Arg Trp Phe Ala Asp Leu Leu Cys Met Leu His 465 470 475 480
- Asn Lys Phe Trp Gln Glu Asn Arg Pro Asp Tyr Val Asn Ile Gln Leu
 485 490 495

Tyr Leu Ser Gln Thr Asp Gly Ile Gln Lys Ile Ile Gly Glu Lys Tyr 500 505 510

His Ala Leu Asn Ser Arg Leu Phe Ile Gly Arg Pro Arg Trp Lys Leu 515 520 525

Leu Phe Asp Glu Ile Ala Lys Tyr Asn Arg Gly Lys Thr Val Gly Val 530 540

Phe Cys Cys Gly Pro Asn Ser Leu Ser Lys Thr Leu His Lys Leu Ser 545 550 555 560

Asn Gln Asn Asn Ser Tyr Gly Thr Arg Phe Glu Tyr Asn Lys Glu Ser 565 570 575

Phe Ser

<210> 9 <211> 2223 <212> DNA

<213> Homo sapiens

<400> gccgacgcgg acggcaacgg ggccatcacc ttcgaggagc tccgggacga gctgcagcgc 60 ttccccggag tcatggagaa cctgaccatc agcactgccc actggctgac ggccccgcc 120 ccccgcccac gcccgcgccg gccgcgccag ctgacccgcg cctactggca caaccaccgc 180 agccagctgt tctgcctggc cacctatgca ggcctccacg tgctgctctt cgggctggcg 240 gccagcgcgc accgggacct cggcgccagc gtcatggtgg ccaagggctg tggccagtgc 300 ctcaacttcg actgcagctt catcgcggtg ctgatgctca gacgctgcct cacctggctg 360 cgggccacgt ggctggctca agtcctacca ctggaccaga acatccagtt ccaccagctt 420 atgggctacg tggtagtggg getgtecete gtgcacactg tggctcacac tgtgaacttt 480 gtactccagg ctcaggcgga ggccagccct ttccagttct gggagctgct gctcaccacg 540 aggeetggea ttggetgggt acaeggtteg geeteeega caggtgtege tetgetgetg 600 ctgctcctcc tcatgttcat ctgctccagt tcctgcatcc gcaggagtgg ccactttgag 660 gtgttctatt ggactcacct gtcctacctc ctcgtgtggc ttctgctcat ctttcatggg 720 cccaacttct ggaagtggct gctggtgcct ggaatcttgt ttttcctgga gaaggccatc 780 ggactggcag tgtcccgcat ggcagccgtg tgcatcatgg aagtcaacct cctccctcc 840 aaggtcactc atctcctcat caagcggccc ccttttttc actatagacc tggtgactac 900 ttgtatctga acatccccac cattgctcgc tatgagtggc accccttcac catcagcagt 960 gctcctgagc agaaagacac tatctggctg cacattcggt cccaaggcca gtggacaaac 1020 aggetgtatg agteetteaa ggeateagae ceaetgggee gtggttetaa gaggetgteg 1080 aggagtgtga caatgagaaa gagtcaaagg tcgtccaagg gctctgagat acttttggag

aaacacaaat tetgtaacat caagtgetac ategatggge ettatgggae eeccaeeege 1200 aggatetttg cetetgagea tgeegtgete ateggggeag geateggeat cacecettt 1260 gcttccattc tgcagagtat catgtacagg caccagaaaa gaaagcatac ttgccccagc 1320 tgccagcact cctggatcga aggtgtccaa gacaacatga agctccataa ggtggacttt 1380 atctggatca acagagacca geggtctttc gagtggtttg tgagcctgct gactaaactg 1440 gagatggacc aggccgagga ggctcaatac ggccgcttcc tggagctgca tatgtacatg 1500 acatctgcac tgggcaagaa tgacatgaag gccattggcc tgcagatggc ccttgacctc 1560 ctggccaaca aggagaagaa agactccatc acggggctgc agacgcgcac ccagcctggg 1620 cggcctgact ggagcaaggt gttccagaaa gtggctgctg agaagaaggg caaggtgcag 1680 gtcttcttct gtggctcccc agctctggcc aaggtgctga agggccattg tgagaagttc 1740 ggcttcagat ttttccaaga gaatttctag cctcacctct ccaagctctg ccccaagtcc 1800 acaccatggg tetgetteat egeattagta taaatgeece cacagggace ageeteagat 1860 gacccaccca ataagacaaa gcctagggac cccctaatcc tgctcaacag agagaacagg 1920 agaccccaag gggcagatga acttcctcta gaacccaggg gaaggggcag tgccttgttc 1980 agtctgctgt agattctggg gtttctgtga aagtgaggga accagaggct ggtcacggga 2040 gcttgggggt ggggttcgag ggggcagagg gcaaccactc ctccaaacat tttccgacgg 2100 agectteece cacatecatg gteccaaace tgeccaatea teacagteat ttggaagett 2160 2220 aaa 2223

<210> 10

<211> 565

<212> PRT

<213> Homo sapiens

<400> 10

A 8 7. 8.

Met Glu Asn Leu Thr Ile Ser Thr Ala His Trp Leu Thr Ala Pro Ala 1 5 10 15

Pro Arg Pro Arg Pro Arg Pro Arg Gln Leu Thr Arg Ala Tyr Trp
20 25 30

His Asn His Arg Ser Gln Leu Phe Cys Leu Ala Thr Tyr Ala Gly Leu 35 40 45

His Val Leu Leu Phe Gly Leu Ala Ala Ser Ala His Arg Asp Leu Gly 50 55 60

Ala Ser Val Met Val Ala Lys Gly Cys Gly Gln Cys Leu Asn Phe Asp 65 70 75 80

Cys Ser Phe Ile Ala Val Leu Met Leu Arg Arg Cys Leu Thr Trp Leu 85 90 95

Arg Ala Thr Trp Leu Ala Gln Val Leu Pro Leu Asp Gln Asn Ile Gln 100 105 110

Phe His Gln Leu Met Gly Tyr Val Val Val Gly Leu Ser Leu Val His 115 120 125

Thr Val Ala His Thr Val Asn Phe Val Leu Gln Ala Gln Ala Glu Ala 130 135 140

Ser Pro Phe Gln Phe Trp Glu Leu Leu Leu Thr Thr Arg Pro Gly Ile 145 150 155 160

Gly Trp Val His Gly Ser Ala Ser Pro Thr Gly Val Ala Leu Leu Leu 165 170 175

Leu Leu Leu Met Phe Ile Cys Ser Ser Ser Cys Ile Arg Arg Ser 180 185 190

Gly His Phe Glu Val Phe Tyr Trp Thr His Leu Ser Tyr Leu Leu Val 195 200 205

Trp Leu Leu Ile Phe His Gly Pro Asn Phe Trp Lys Trp Leu Leu 210 215 220

Val Pro Gly Ile Leu Phe Phe Leu Glu Lys Ala Ile Gly Leu Ala Val 225 235 240

Ser Arg Met Ala Ala Val Cys Ile Met Glu Val Asn Leu Leu Pro Ser 245 250 255

Lys Val Thr His Leu Leu Ile Lys Arg Pro Pro Phe Phe His Tyr Arg 260 265 270

Pro Gly Asp Tyr Leu Tyr Leu Asn Ile Pro Thr Ile Ala Arg Tyr Glu 275 280 285

Trp His Pro Phe Thr Ile Ser Ser Ala Pro Glu Gln Lys Asp Thr Ile 290 295 300

Trp Leu His Ile Arg Ser Gln Gly Gln Trp Thr Asn Arg Leu Tyr Glu 305 310 315 320

Ser Phe Lys Ala Ser Asp Pro Leu Gly Arg Gly Ser Lys Arg Leu Ser 325 330 335

Arg Ser Val Thr Met Arg Lys Ser Gln Arg Ser Ser Lys Gly Ser Glu 340 345 350

Ile Leu Leu Glu Lys His Lys Phe Cys Asn Ile Lys Cys Tyr Ile Asp 355 360 365

Gly Pro Tyr Gly Thr Pro Thr Arg Arg Ile Phe Ala Ser Glu His Ala 370 380

Val Leu Ile Gly Ala Gly Ile Gly Ile Thr Pro Phe Ala Ser Ile Leu 385 390 395 400 WO 03/087399 PCT/SE03/00618

16/61 Gln Ser Ile Met Tyr Arg His Gln Lys Arg Lys His Thr Cys Pro Ser 405 Cys Gln His Ser Trp Ile Glu Gly Val Gln Asp Asn Met Lys Leu His Lys Val Asp Phe Ile Trp Ile Asn Arg Asp Gln Arg Ser Phe Glu Trp Phe Val Ser Leu Leu Thr Lys Leu Glu Met Asp Gln Ala Glu Glu Ala Gln Tyr Gly Arg Phe Leu Glu Leu His Met Tyr Met Thr Ser Ala Leu Gly Lys Asn Asp Met Lys Ala Ile Gly Leu Gln Met Ala Leu Asp Leu 485 490 Leu Ala Asn Lys Glu Lys Lys Asp Ser Ile Thr Gly Leu Gln Thr Arg Thr Gln Pro Gly Arg Pro Asp Trp Ser Lys Val Phe Gln Lys Val Ala Ala Glu Lys Lys Gly Lys Val Gln Val Phe Phe Cys Gly Ser Pro Ala Leu Ala Lys Val Leu Lys Gly His Cys Glu Lys Phe Gly Phe Arg Phe Phe Gln Glu Asn Phe 565 <210> 11 <211> 5494 <212> DNA

<213> Homo sapiens

<400> 11 gcagagetgc agaggcaccg gacgagagag ggctccgcgg gcccagctgg cagccaggcc 60 ggagacaagt tgcagtcccg ggctctggtg acgccgtggc cgcagggtct ccattttggg 120 acattctaat ccctgagccc ctattatttt catcatgggc ttctgcctgg ctctagcatg 180 gacacttctg gttggggcat ggacccctct gggagctcag aaccccattt cgtgggaggt 240 gcagcgattt gatgggtggt acaacaacct catggagcac agatggggca gcaaaggetc 300 ccggctgcag cgcctggtcc cagccagcta tgcagatggc gtgtaccagc ccttgggaga 360 accecacetg eccaaceee gagacettag caacaceate teaaggggee etgeaggget 420 ggcctccctg agaaaccgca cagtgttggg ggtcttcttt ggctatcacg tgctttcaga 480 cctggtgagc gtggaaactc ccggctgccc cgccgagttc ctcaacattc gcatcccgcc 540

cggagaccc	c atgttcgacc	ccgaccagcg	g cggggacgt	g gtgctgccct	tccagagaag	600
ccgctggga	c cccgagaccg	gacggagted	cagcaatcc	c cgggacccgg	g ccaaccaggt	660
gacgggctg	g ctggacggca	gegecateta	tggttcctc	g cattcctgga	gcgacgcgct	720
gcggagctt	c tecaggggae	agctggcgtc	ggggcccga	c cccgcttttc	cccgagactc	780
gcagaaccc	c ctgctcatgt	gggcggcgcc	: cgaccccgc	c accgggcaga	acgggccccg	840
ggggctgtad	gccttcgggg	cagagagagg	gaaccgggaa	a cccttcctgc	aggcgctggg	900
cctgctctgg	g ttccgctacc	acaacctgtg	ggcgcagagg	g ctggcccgcc	agcacccaga	960
ctgggaggac	gaggagetgt	tccagcacgc	acgcaagagg	g gtcatcgcca	cctaccagaa	1020
categetgte	g tatgagtggc	tgcccagctt	cctgcagaaa	acactcccgg	agtatacagg	1080
ataccggcca	tttctggacc	ccagcatctc	ctcagagttc	gtggcggcct	ctgagcagtt	1140
cctgtccacc	atggtgcccc	ctggcgtcta	catgagaaat	gccagctgcc	acttccaggg	1200
ggtcatcaat	: cggaactcaa	gtgtctccag	agctctccgg	gtctgcaaca	gctactggag	1260
ccgtgagcac	: ccaagcctac	aaagtgctga	agatgtggat	gcactgctgc	tgggcatggc	1320
ctcccagato	gcagagcgag	aggaccatgt	gttggttgaa	gatgtgcggg	atttctggcc	1380
tgggccactg	aagttttccc	gcacagacca	cctggccagc	tgcctgcagc	ggggccggga	1440
tctgggcctg	ccctcttaca	ccaaggccag	ggcagcactg	ggcttgtctc	ccattacccg	1500
ctggcaggac	atcaaccctg	cactctcccg	gagcaatgac	actgtactgg	aggccacagc	1560
tgccctgtac	aaccaggact	tatcctggct	agagctgctc	cctgggggac	tcctggagag	1620
ccaccgggac	cctggacctc	tgttcagcac	catcgtcctt	gaacaatttg	tgcggctacg	1680
ggatggtgac	cgctactggt	ttgagaacac	caggaatggg	ctgttctcca	agaaggagat	1740
tgaagaaatc	cgaaatacca	ccctgcagga	cgtgctggtc	gctgttatca	acattgaccc	1800
cagtgctctg	cagcccaatg	tctttgtctg	gcataaagga	gacccctgtc	cgcagccgag	1860
acageteage	actgaaggcc	tgccagcgtg	tgctccctct	gttgttcgtg	actattttga	1920
gggcagtgga	tttggcttcg	gggtcaccat	cgggaccctc	tgttgcttcc	ctttggtgag	1980
cctgctcagt	gcctggattg	ttgcccggct	ccggatgaga	aatttcaaga	ggctccaggg	2040
ccaggaccgc	cagagcatcg	tgtctgagaa	gctcgtggga	ggcatggaag	ctttggaatg	2100
gcaaggccac	aaggagccct	gccggcccgt	gcttgtgtac	ctgcagcccg	ggcagatecg	2160
tgtggtagat	ggcaggctca	ccgtgctccg	caccatccag	ctgcagcctc	cacagaaggt	2220
caacttcgtc	ctgtccagca	accgtggacg	ccgcactctg	ctgctcaaga	tccccaagga	2280
gtatgacctg	gtgctgctgt	ttaacttgga	ggaagagcgg	caggcgctgg	tggaaaatct	2340

gacggtgcaa cagttcaagc gcttcattga gaactaccgg cgccacatcg gctgcgtggc cgtgttctac gccatcgctg gggggctttt cctggagagg gcctactact acgcctttgc cgcacatcac acgggcatca cggacaccac ccgcgtggga atcatcctgt cgcggggcac agcagccagc atctctttca tgttctccta catcttgctc accatgtgcc gcaacctcat caccttcctg cgagaaacct tectcaaccg ctacgtgccc ttcgacgccg ccgtggactt ccatcgcctc attgcctcca ccgccatcgt cctcacagtc ttacacagtg tgggccatgt ggtgaatgtg tacctgttct ccatcagccc cctcagcgtc ctctcttgcc tctttcctgg cctcttccat gatgatgggt ctgagttccc ccagaagtat tactggtggt tcttccagac cgtaccaggc ctcacggggg ttgtgctgct cctgatcctg gccatcatgt atgtctttgc 3780 ctcccaccac ttccgccgcc gcagtttccg gggcttctgg ctgacccacc acctctacat 3840 . cotgetetat gteetgetea teatecatgg tagetttgee etgatecage tgeecegttt 3900 ccacatcttc ttcctggtcc cagcaatcat ctatgggggc gacaagctgg tgagcctgag 3960 ccggaagaag gtggagatca gcgtggtgaa ggcggagctg ctgccctcag gagtgaccca 4020 cctgcggttc cagcggcccc agggctttga gtacaagtca gggcagtggg tgcggatcgc 4080 ttgcctggct ctggggacca ccgagtacca ccccttcaca ctgacctctg cgccccatga 4140 ggacacgett ageetgeaca teegggeage agggeeetgg accaetegee teagggagat 4200

ctactcagcc	ccgacgggtg	acagatgtgc	cagataccca	aagctgtacc	ttgatggacc	4260
atttggagag	ggccaccagg	agtggcataa	gtttgaggtg	tcagtgttag	tgggagggg	4320
cattggggtc	accccttttg	cctccatcct	caaagacctg	gtcttcaagt	catccgtcag	4380
ctgccaagtg	ttctgtaaga	agatctactt	catctgggtg	acgcggaccc	agcgtcagtt	4440.
tgagtggctg	gctgacatca	teegagaggt	ggaggagaat	gaccaccagg	acctggtgtc	4500
tgtgcacatc	tacatcaccc	agctggctga	gaagttcgac	ctcaggacca	ctatgctgta	4560
catctgtgag	cggcacttcc	agaaggttct	gaaccggagt	ctattcacag	gcctgcgctc	4620
catcacccac	tttggccgtc	cccctttga	gcccttcttc	aactccctgc	aggaggtcca	4680
ccccaggtc	cggaagatcg	gggtgtttag	ctgtggcccc	cctggcatga	ccaagaatgt	4740
ggaaaaggcc	tgtcagctca	tcaacaggca	ggaccggact	cacttctccc	accattatga	4800
gaacttctag	gcccctgccc	gggggttctg	cccactgtcc	agttgagcag	aggtttgagc	4860
ccacacctca	cctctgttct	tcctatttct	ggctgcctca	gccttctctg	atttcccacc	4920
tcccaacctt	gttccaggtg	gccatagtca	gtcaccatgt	gtgggctcag	ggacccccag	4980
gaccaggatg	tgtctcagcc	tggagaaatg	gtggggggc	agtgtctagg	gactagagtg	5040
agaagtaggg	gagctactga	tttggggcaa	agtgaaacct	ctgcttcaga	cttcagaaac	5100
aaatctcaga	agacaagctg	acctgacaag	tactatgtgt	gtgcatgtct	gtatgtgtgt	5160
tggggcggtg	agtgtaagga	tgcagtggga	gcatggatgc	tggcatctta	gaaccctccc	5220
tactcccata	cctcctcctc	ttctgggctc	cccactgtca	gacgggctgg	caaatgcctt	5280
gcaggaggta	gaggetggae	ccatggcaag	ccatttacag	aaacccactc	ggcaccccag	5340
tctaacacca	caactaattt	cacccaaggt	tttaagcacg	ttctttcatc	agaccctggc	5400
ccaataccta	tgtatgcaat	gctcctcagc	cctcttctcc	ctgctccagt	agtctccctt	5460
ccaaataaat	cacttttctg	ccaaaaaaaa	aaaa			5494

<210> 12

<400> 12

Met Gly Phe Cys Leu Ala Leu Ala Trp Thr Leu Leu Val Gly Ala Trp 1 5 10 15

Thr Pro Leu Gly Ala Gln Asn Pro Ile Ser Trp Glu Val Gln Arg Phe 20 25 30

<211> 1551

<212> PRT

<213> Homo sapiens

Asp Gly Trp Tyr Asn Asn Leu Met Glu His Arg Trp Gly Ser Lys Gly

Ser Arg Leu Gln Arg Leu Val Pro Ala Ser Tyr Ala Asp Gly Val Tyr 55

Gln Pro Leu Gly Glu Pro His Leu Pro Asn Pro Arg Asp Leu Ser Asn

Thr Ile Ser Arg Gly Pro Ala Gly Leu Ala Ser Leu Arg Asn Arg Thr

Val Leu Gly Val Phe Phe Gly Tyr His Val Leu Ser Asp Leu Val Ser

Val Glu Thr Pro Gly Cys Pro Ala Glu Phe Leu Asn Ile Arg Ile Pro

Pro Gly Asp Pro Met Phe Asp Pro Asp Gln Arg Gly Asp Val Val Leu 135

Pro Phe Gln Arg Ser Arg Trp Asp Pro Glu Thr Gly Arg Ser Pro Ser 150

Asn Pro Arg Asp Pro Ala Asn Gln Val Thr Gly Trp Leu Asp Gly Ser 165

Ala Ile Tyr Gly Ser Ser His Ser Trp Ser Asp Ala Leu Arg Ser Phe 185

Ser Arg Gly Gln Leu Ala Ser Gly Pro Asp Pro Ala Phe Pro Arg Asp 200

Ser Gln Asn Pro Leu Leu Met Trp Ala Ala Pro Asp Pro Ala Thr Gly 215

Gln Asn Gly Pro Arg Gly Leu Tyr Ala Phe Gly Ala Glu Arg Gly Asn 235

Arg Glu Pro Phe Leu Gln Ala Leu Gly Leu Leu Trp Phe Arg Tyr His 250

Asn Leu Trp Ala Gln Arg Leu Ala Arg Gln His Pro Asp Trp Glu Asp

Glu Glu Leu Phe Gln His Ala Arg Lys Arg Val Ile Ala Thr Tyr Gln 280

Asn Ile Ala Val Tyr Glu Trp Leu Pro Ser Phe Leu Gln Lys Thr Leu 295

Pro Glu Tyr Thr Gly Tyr Arg Pro Phe Leu Asp Pro Ser Ile Ser Ser 315

Glu Phe Val Ala Ala Ser Glu Gln Phe Leu Ser Thr Met Val Pro Pro

Gly Val Tyr Met Arg Asn Ala Ser Cys His Phe Gln Gly Val Ile Asn 345

Arg Asn Ser Ser Val Ser Arg Ala Leu Arg Val Cys Asn Ser Tyr Trp 355 360 365

Ser Arg Glu His Pro Ser Leu Gln Ser Ala Glu Asp Val Asp Ala Leu 370 380

Leu Leu Gly Met Ala Ser Gln Ile Ala Glu Arg Glu Asp His Val Leu 385 390 395 400

Val Glu Asp Val Arg Asp Phe Trp Pro Gly Pro Leu Lys Phe Ser Arg
405 410 415

Thr Asp His Leu Ala Ser Cys Leu Gln Arg Gly Arg Asp Leu Gly Leu 420 425 430

Pro Ser Tyr Thr Lys Ala Arg Ala Ala Leu Gly Leu Ser Pro Ile Thr 435 440 445

Arg Trp Gln Asp Ile Asn Pro Ala Leu Ser Arg Ser Asn Asp Thr Val 450 455 460

Leu Glu Ala Thr Ala Ala Leu Tyr Asn Gln Asp Leu Ser Trp Leu Glu 465 470 475 480

Leu Leu Pro Gly Gly Leu Leu Glu Ser His Arg Asp Pro Gly Pro Leu
485 490 495

Phe Ser Thr Ile Val Leu Glu Gln Phe Val Arg Leu Arg Asp Gly Asp 500 505 510

Arg Tyr Trp Phe Glu Asn Thr Arg Asn Gly Leu Phe Ser Lys Lys Glu 515 520 525

Ile Glu Glu Ile Arg Asn Thr Thr Leu Gln Asp Val Leu Val Ala Val 530 540

Ile Asn Ile Asp Pro Ser Ala Leu Gln Pro Asn Val Phe Val Trp His 545 550 555 560

Lys Gly Asp Pro Cys Pro Gln Pro Arg Gln Leu Ser Thr Glu Gly Leu 565 570 575

Pro Ala Cys Ala Pro Ser Val Val Arg Asp Tyr Phe Glu Gly Ser Gly 580 585 590

Phe Gly Phe Gly Val Thr Ile Gly Thr Leu Cys Cys Phe Pro Leu Val 595 600 605

Ser Leu Leu Ser Ala Trp Ile Val Ala Arg Leu Arg Met Arg Asn Phe 610 615 620

Lys Arg Leu Gln Gly Gln Asp Arg Gln Ser Ile Val Ser Glu Lys Leu 625 630 635 640

Val Gly Gly Met Glu Ala Leu Glu Trp Gln Gly His Lys Glu Pro Cys
645 650 655

Arg Pro Val Leu Val Tyr Leu Gln Pro Gly Gln Ile Arg Val Val Asp
660 665 670

Gly Arg Leu Thr Val Leu Arg Thr Ile Gln Leu Gln Pro Pro Gln Lys 675 680 685

Val Asn Phe Val Leu Ser Ser Asn Arg Gly Arg Arg Thr Leu Leu Leu 690 695 700

Lys Ile Pro Lys Glu Tyr Asp Leu Val Leu Leu Phe Asn Leu Glu Glu 705 710 715 720

Glu Arg Gln Ala Leu Val Glu Asn Leu Arg Gly Ala Leu Lys Glu Ser 725 730 735

Gly Leu Ser Ile Gln Glu Trp Glu Leu Arg Glu Gln Glu Leu Met Arg
740 745 750

Ala Ala Val Thr Arg Glu Gln Arg Arg His Leu Leu Glu Thr Phe Phe 755 760 765

Arg His Leu Phe Ser Gln Val Leu Asp Ile Asn Gln Ala Asp Ala Gly 770 775 780

Thr Leu Pro Leu Asp Ser Ser Gln Lys Val Arg Glu Ala Leu Thr Cys
785 790 795 800

Glu Leu Ser Arg Ala Glu Phe Ala Glu Ser Leu Gly Leu Lys Pro Gln 805 810 815

Asp Met Phe Val Glu Ser Met Phe Ser Leu Ala Asp Lys Asp Gly Asn 820 825 830

Gly Tyr Leu Ser Phe Arg Glu Phe Leu Asp Ile Leu Val Val Phe Met 835 840 845

Lys Gly Ser Pro Glu Glu Lys Ser Arg Leu Met Phe Arg Met Tyr Asp 850 855 860

Phe Asp Gly Asn Gly Leu Ile Ser Lys Asp Glu Phe Ile Arg Met Leu 865 870 875 880

Arg Ser Phe Ile Glu Ile Ser Asn Asn Cys Leu Ser Lys Ala Gln Leu 885 890 895

Ala Glu Val Val Glu Ser Met Phe Arg Glu Ser Gly Phe Gln Asp Lys 900 905 910

Glu Glu Leu Thr Trp Glu Asp Phe His Phe Met Leu Arg Asp His Asn 915 920 925

Ser Glu Leu Arg Phe Thr Gln Leu Cys Val Lys Gly Val Glu Val Pro 930 935 940

Glu Val Ile Lys Asp Leu Cys Arg Arg Ala Ser Tyr Ile Ser Gln Asp 945 950 955 960

Met Ile Cys Pro Ser Pro Arg Val Ser Ala Arg Cys Ser Arg Ser Asp 965 970 975

Ile Glu Thr Glu Leu Thr Pro Gln Arg Leu Gln Cys Pro Met Asp Thr 980 985 990

Asp Pro Pro Gln Glu Ile Arg Arg Phe Gly Lys Lys Val Thr Ser

Phe Gln Pro Leu Leu Phe Thr Glu Ala His Arg Glu Lys Phe Gln 1010 1015 1020

Arg Ser Cys Leu His Gln Thr Val Gln Gln Phe Lys Arg Phe Ile 1025 1030 1035

Glu Asn Tyr Arg Arg His Ile Gly Cys Val Ala Val Phe Tyr Ala 1040 1045 1050

Ile Ala Gly Gly Leu Phe Leu Glu Arg Ala Tyr Tyr Tyr Ala Phe 1055 1060 1065

Ala Ala His His Thr Gly Ile Thr Asp Thr Thr Arg Val Gly Ile 1070 1075 1080

Ile Leu Ser Arg Gly Thr Ala Ala Ser Ile Ser Phe Met Phe Ser 1085 1090 1095

Tyr Ile Leu Leu Thr Met Cys Arg Asn Leu Ile Thr Phe Leu Arg

Glu Thr Phe Leu Asn Arg Tyr Val Pro Phe Asp Ala Ala Val Asp 1115 1120 1125

Phe His Arg Leu Ile Ala Ser Thr Ala Ile Val Leu Thr Val Leu 1130 1140

His Ser Val Gly His Val Val Asn Val Tyr Leu Phe Ser Ile Ser 1145 1150 1155

Pro Leu Ser Val Leu Ser Cys Leu Phe Pro Gly Leu Phe His Asp

Asp Gly Ser Glu Phe Pro Gln Lys Tyr Tyr Trp Trp Phe Phe Gln 1175

Thr Val Pro Gly Leu Thr Gly Val Val Leu Leu Leu Ile Leu Ala 1190 1195 1200

Ile Met Tyr Val Phe Ala Ser His His Phe Arg Arg Arg Ser Phe 1205 1210 1215

Arg Gly Phe Trp Leu Thr His His Leu Tyr Ile Leu Leu Tyr Val

Leu Leu Ile Ile His Gly Ser Phe Ala Leu Ile Gln Leu Pro Arg

Phe His Ile Phe Phe Leu Val Pro Ala Ile Ile Tyr Gly Gly Asp 1250 1255 1260

Lys Leu Val Ser Leu Ser Arg Lys Lys Val Glu Ile Ser Val Val 1265 1270 1275

Lys Ala Glu Leu Leu Pro Ser Gly Val Thr His Leu Arg Phe Gln 1280 1285 1290

24/61
Arg Pro Gln Gly Phe Glu Tyr Lys Ser Gly Gln Trp Val Arg Ile
1295 1300 1305

Ala Cys Leu Ala Leu Gly Thr Thr Glu Tyr His Pro Phe Thr Leu

1315

Thr Ser Ala Pro His Glu Asp Thr Leu Ser Leu His Ile Arg Ala 1325 1330 1335

Ala Gly Pro Trp Thr Thr Arg Leu Arg Glu Ile Tyr Ser Ala Pro 1340 1345 1350

Thr Gly Asp Arg Cys Ala Arg Tyr Pro Lys Leu Tyr Leu Asp Gly 1355

Pro Phe Gly Glu Gly His Gln Glu Trp His Lys Phe Glu Val Ser 1370 1375 1380

Val Leu Val Gly Gly Gly Ile Gly Val Thr Pro Phe Ala Ser Ile 1385 1390 1395

Leu Lys Asp Leu Val Phe Lys Ser Ser Val Ser Cys Gln Val Phe 1400 1405 1410

Cys Lys Lys Ile Tyr Phe Ile Trp Val Thr Arg Thr Gln Arg Gln 1415 1420 1425

Phe Glu Trp Leu Ala Asp Ile Ile Arg Glu Val Glu Glu Asn Asp 1430 1435 1440

His Gln Asp Leu Val Ser Val His Ile Tyr Ile Thr Gln Leu Ala 1445 1450 1455

Glu Lys Phe Asp Leu Arg Thr Thr Met Leu Tyr Ile Cys Glu Arg 1460 1465 1470

His Phe Gln Lys Val Leu Asn Arg Ser Leu Phe Thr Gly Leu Arg

Ser Ile Thr His Phe Gly Arg Pro Pro Phe Glu Pro Phe Phe Asn 1490 1495 1500

Ser Leu Gln Glu Val His Pro Gln Val Arg Lys Ile Gly Val Phe 1505 1510 1515

Ser Cys Gly Pro Pro Gly Met Thr Lys Asn Val Glu Lys Ala Cys 1520 1525 1530

Gln Leu Ile Asn Arg Gln Asp Arg Thr His Phe Ser His His Tyr 1535 1540 1545

Glu Asn Phe 1550

والمتهامة

<210> 13

<211> 6375

<212> DNA

<213> Homo sapiens

<400> 13 ggtctgtcct gagccgacac ctgcacagtg gcgagaccaa ggacccagag agaaaggtga 60 gagtgcagcc ggggaggctg aggatcggcg gagctggaag agtgagggtg aaggcaagaa 120 gtagagcaca gaagcaaaga ttttaagagg aaagaagaca tttgaaccca acaccaccct 180 aaaccacagg ctgcagggtt ggcatgctcc gtgcaagacc agaggcactg atgctcctgg 240 gagetettet gaetggatee etgggteeat egggeagtea ggaegeacte teaetgeeet 300 gggaagtgca gcgctatgac ggctggttta acaacctgag gcaccacgag cgtggtgctg 360 ttggctgccg gttgcagcgc cgcgtaccag ccaattacgc cgacggtgtg tatcaggctc 420 tggaggagcc gcagctgccc aacccgcgcc ggctcagcaa cgcagccacg cggggcatag 480 ecggeetgee gtegeteeac aacegeaceg tactgggggt ettetttgge taccatgtte 540 tttccgacgt ggtgagcgtg gaaacgcccg gttgccccgc cgagttcctc aacatccgca 600 teccaectgg agaectegtg ttegaeceeg accagegegg ggaegtggtg etgecettee 660 agaggageeg etgggaeece gagaeeggae ggagteecag caaceeegg gaeetggeea 720 accaggtgac gggctggctg gacggcagcg ccatctatgg ctcctcgcac tcctggagcg 780 acgegetgeg gagetteteg gggggacage tggegteggg geeegaceee gettteeeee 840 gagactegea gaaccccetg etcatgtggg eggegeeega eccegeeace gggeagaaeg. 900 ggccccgggg gctgtacgcc ttcggggcag agagagggaa ccgggaaccc ttcctgcagg 960 cgctgggcct gctctggttc cgctaccaca acctgtgggc gcagaggctg gcccgccagc 1020 acccagactg ggaggacgag gagctgttcc agcacgcacg caagagggtc atcgccacct 1080 accagaacat cgctgtgtat gagtggctgc ccagcttcct gcagaaaaca ctcccggagt 1140 atacaggata cogtoottto ctagaccoca gcatotococ ggaatttgtg gtggcototg 1200 agcagttett etetaceatg gtgeceeetg gtgtetacat gagaaatgee agetgteatt 1260 tccggaaggt cctgaacaag ggttttcaaa gctcccaagc tctcagggtc tgcaacaact 1320 actggattcg ggagaacccc aatctgaaca gtacccagga ggtgaatgag ctgctgctgg 1380 gaatggcctc ccagatttcg gagttggagg acaacatagt ggttgaagat ctgagggatt 1440 actggcctgg ccctggcaaa ttctcccgta cagactatgt ggccagcagc atccaacgtg 1500 gccgagatat ggggctgccc agctatagcc aggccctgct ggcctttggg ctggacatcc 1560 caaggaactg gagtgatctc aaccctaatg tggaccccca ggtgctggag gccacagetg 1620 ccctgtacaa ccaggaccta tcccagctag agctgctcct tggcgggctc ctggagagcc 1680 atggggaccc tggacccctg ttcagtgcca ttgtcctcga ccagtttgta cggctgcggg 1740 atggtgaccg ctactggttt gagaacacca ggaatgggct gttctccaag aaggagattg 1800

ctgctgttgt cctggccatt ttgcacagtg ctggccacgc agtcaatgtc tacatcttct

3660

WO 03/087399 PCT/SE03/00618

cagtcagcc	c actcagecte	g ctggcctgca	tattcccca	a cgtctttgtg	aatgatgggt	3720
ccaagette	c ccagaagtto	: tattggtggt	tcttccaga	c cgtcccaggt	atgacaggtg	3780
tgcttctgc	t cctggtcctg	gccatcatgt	atgtcttcg	c ctcccaccac	: ttccgccgcc	3840
gcagcttccg	g gggettetgg	ctgacccacc	acctctacat	cctgctctat	gccctgctca	3900
tcatccatgo	g cagctatgct	ctgatccago	tgcccacttt	ccacatctac	ttcctggtcc	3960
cggcaatcat	ctatggaggt	gacaagctgg	tgagcctgag	g ccggaagaag	gtggagatca	4020
gcgtggtgaa	ggcggagctg	ctgccctcag	gagtgaecta	a cctgcaatto	cagaggeece	4080
aaggctttga	gtacaagtca	ggacagtggg	tgcggatcgc	ctgcctggct	ctggggacca	4140
ccgagtacca	cccttcaca	ctgacctccg	cgccccatga	ggacacactc	agcctgcaca	4200
tccgggcagt	ggggccctgg	accactcgcc	tcagggagat	ctactcatcc	ccaaagggca	4260
atggctgtgc	tggataccca	aagctgtacc	ttgatggaco	gtttggagag	ggccatcagg	4320
agtggcataa	atttgaggtg	tcagtgttgg	tgggagggg	cattggggtc	accccctttg	4380
cctccatcct	caaagacctg	gtcttcaagt	catccttggg	cagccaaatg	ctgtgtaaga	4440
agatctactt	catctgggtg	acacggaccc	agcgtcagtt	tgagtggctg	gctgacatca	4500
tccaagaggt	ggaggagaac	gaccaccagg	acctggtgtc	tgtgcacatt	tatgtcaccc	4560
agctggctga	gaagttcgac	ctcaggacca	ccatgctata	catctgcgag	cggcacttcc	4620
agaaagtgct	gaaccggagt	ctgttcacgg	gcctgcgctc	catcacccac	tttggccgtc	4680
ccccttcga	gcccttcttc	aactccctgc	aggaggtcca	cccacaggtg	cgcaagatcg	4740
gggtgttcag	ctgcggccct	ccaggaatga	ccaagaatgt	agagaaggcc	tgtcagctcg	4800
tcaacaggca	ggaccgagcc	cacttcatgc	accactatga	gaacttctga	gcctgtcctc	4860
cctggctgct	gcttccagta	tcctgccttc	tcttctgtgc	acctaagttg	cccagccctg	4920
ctggcaatct	ctccatcaga	atccacctta	ggcctcagct	ggagggctgc	agagcccctc	4980
ccaatattgg	gagaatattg	acccagacaa	ttatacaaat	gagaaaaggc	aggagactat	5040
gttctacaat	tgcagtgcat	gatgattata	agtccacctg	tttatcaacg	gcaccattcc	5100
tgcagccctc	cagacttcct	gcccttagca	agtgcgcaac	cagtcaggat	ctcccaaaga	5160
agataaagac	cactcctcac	cccagctcaa	gccatggcag	gcgtggcaag	caaagtgggg	5220
aggagacagt	ccctgcttgt	gacaagtgtg	gaggtgaaaa	ggtcaatagt	gcttgtctcc	5280
gatagetece	cacatctcta	attgacttcc	acaaaatcga	tgegttgett	tggtatttgc	5340
ttggactgac	atttgaggga	ggaggaggct	gggatcctct	ggctgagaat	ctcctcagag	5400
cccagtgcag	aagctgtgat	gcttagaacc	tggacagccc	gactgcctca	actctgtctc	5460

WO 03/087399				PCT	SE03/00
		28/61			
caggtctatt ccctccagct	ccaaaaggag	cagccctact	tctacccctt	ccegtcccca	5520
aagtgtcagc aactttgagg	g agggcaccag	gaaacaaaga	tgccttccca	gccctgatat	5580
tcttgatgtc accagtgata	cccactgccc	tgacccctgg	gcaggcccct	ctctgcatct	5640
actggagtgg tccctgggct	cttggggctg	aaggattcca	gcctctctgc	cagatattca	5700
gtactcgatc tcaattcccc	: tcttccacaa	gagttgggtg	accagctgtc	ctagtttgcc	5760
caggactete cetgttttag	cactgaaagt	ctcttgcccc	aggaaacccc	atcagtccca	5820
ggcagattgg gacagctggt	caccttacgc	aagagccagg	ctgaaacatc	ccctccatac	5880
tcagctcttt aacttttctt	ttcctttttc	atcgggctct	ttcctaaaaa	gctgagctgt	5940
aaaatatttt acatcgaggt	ataataaata	atcatgtaca	tgttttacca	ccacccaggt	6000
caagacatag aatgtttcaa	catttccatc	accccagaaa	ctccccttgt	accccttcc	6060
cttcgtctcc cctagctcct	agaagcaacc	actgatgtga	tttctaccaa	atccagtttt	6120
ggtcctacta aatatactct	tttgagactg	gcctctttta	ctcaccataa	tgcctttgta	6180
attcatccat gctgttgtgt	gtatcagcag	tttgttcctt	ttcattgctg	agtagtattc	6240
tattgtagag atgtaccaca	gtttgtttat	tettetgttg	atggacgttt	gggttgtttc	6300
taattttgaa tgattataaa	taaaaattct	gtgagtgttc	ttgtaaaaaa	aaaaaaaaa	6360
aaaaaaaaa aaaaa					6375
<210> 14 <211> 1548 <212> PRT <213> Homo sapiens					
<400> 14 Met Leu Arg Ala Arg Pr	o Glu Ala L	eu Met Leu	Leu Gly Ala	Leu Leu	

10

Thr Gly Ser Leu Gly Pro Ser Gly Ser Gln Asp Ala Leu Ser Leu Pro

Trp Glu Val Gln Arg Tyr Asp Gly Trp Phe Asn Asn Leu Arg His His

Glu Arg Gly Ala Val Gly Cys Arg Leu Gln Arg Arg Val Pro Ala Asn

Tyr Ala Asp Gly Val Tyr Gln Ala Leu Glu Glu Pro Gln Leu Pro Asn

Pro Arg Arg Leu Ser Asn Ala Ala Thr Arg Gly Ile Ala Gly Leu Pro

Ser Leu His Asn Arg Thr Val Leu Gly Val Phe Phe Gly Tyr His Val 100

Leu Ser Asp Val Val Ser Val Glu Thr Pro Gly Cys Pro Ala Glu Phe 120

- Leu Asn Ile Arg Ile Pro Pro Gly Asp Leu Val Phe Asp Pro Asp Gln
 130 135 140
- Arg Gly Asp Val Val Leu Pro Phe Gln Arg Ser Arg Trp Asp Pro Glu
 145 150 155 160
- Thr Gly Arg Ser Pro Ser Asn Pro Arg Asp Leu Ala Asn Gln Val Thr
 165 170 175
- Gly Trp Leu Asp Gly Ser Ala Ile Tyr Gly Ser Ser His Ser Trp Ser 180 185 190
- Asp Ala Leu Arg Ser Phe Ser Gly Gly Gln Leu Ala Ser Gly Pro Asp 195 200 205
- Pro Ala Phe Pro Arg Asp Ser Gln Asn Pro Leu Leu Met Trp Ala Ala 210 215 220
- Pro Asp Pro Ala Thr Gly Gln Asn Gly Pro Arg Gly Leu Tyr Ala Phe 225 230 235 240
- Gly Ala Glu Arg Gly Asn Arg Glu Pro Phe Leu Gln Ala Leu Gly Leu 245 250 255
- Leu Trp Phe Arg Tyr His Asn Leu Trp Ala Gln Arg Leu Ala Arg Gln 260 265 270
- His Pro Asp Trp Glu Asp Glu Glu Leu Phe Gln His Ala Arg Lys Arg 275 280 285
 - Val Ile Ala Thr Tyr Gln Asn Ile Ala Val Tyr Glu Trp Leu Pro Ser 290 295 300
 - Phe Leu Gln Lys Thr Leu Pro Glu Tyr Thr Gly Tyr Arg Pro Phe Leu 305 310 315 320
 - Asp Pro Ser Ile Ser Pro Glu Phe Val Val Ala Ser Glu Gln Phe Phe 325 330 335
 - Ser Thr Met Val Pro Pro Gly Val Tyr Met Arg Asn Ala Ser Cys His 340 345 350
 - Phe Arg Lys Val Leu Asn Lys Gly Phe Gln Ser Ser Gln Ala Leu Arg 355 360 365
- Val Cys Asn Asn Tyr Trp Ile Arg Glu Asn Pro Asn Leu Asn Ser Thr 370 380
- Gln Glu Val Asn Glu Leu Leu Leu Gly Met Ala Ser Gln Ile Ser Glu 385 390 395 400
- Leu Glu Asp Asn Ile Val Val Glu Asp Leu Arg Asp Tyr Trp Pro Gly 405 410 415
- Pro Gly Lys Phe Ser Arg Thr Asp Tyr Val Ala Ser Ser Ile Gln Arg 420 425 430
- Gly Arg Asp Met Gly Leu Pro Ser Tyr Ser Gln Ala Leu Leu Ala Phe
 435 440 445

Gly Leu Asp Ile Pro Arg Asn Trp Ser Asp Leu Asn Pro Asn Val Asp 455

Pro Gln Val Leu Glu Ala Thr Ala Ala Leu Tyr Asn Gln Asp Leu Ser

Gln Leu Glu Leu Leu Gly Gly Leu Leu Glu Ser His Gly Asp Pro 485

Gly Pro Leu Phe Ser Ala Ile Val Leu Asp Gln Phe Val Arg Leu Arg

Asp Gly Asp Arg Tyr Trp Phe Glu Asn Thr Arg Asn Gly Leu Phe Ser 520

Lys Lys Glu Ile Glu Asp Ile Arg Asn Thr Thr Leu Arg Asp Val Leu

Val Ala Val Ile Asn Ile Asp Pro Ser Ala Leu Gln Pro Asn Val Phe 550 555

Val Trp His Lys Gly Ala Pro Cys Pro Gln Pro Lys Gln Leu Thr Thr

Asp Gly Leu Pro Gln Cys Ala Pro Leu Thr Val Leu Asp Phe Phe Glu

Gly Ser Ser Pro Gly Phe Ala Ile Thr Ile Ile Ala Leu Cys Cys Leu

Pro Leu Val Ser Leu Leu Ser Gly Val Val Ala Tyr Phe Arg Gly 615

Arg Glu His Lys Lys Leu Gln Lys Lys Leu Lys Glu Ser Val Lys Lys 630

Glu Ala Ala Lys Asp Gly Val Pro Ala Met Glu Trp Pro Gly Pro Lys

Glu Arg Ser Ser Pro Ile Ile Ile Gln Leu Leu Ser Asp Arg Cys Leu 665

Gln Val Leu Asn Arg His Leu Thr Val Leu Arg Val Val Gln Leu Gln 680

Pro Leu Gln Gln Val Asn Leu Ile Leu Ser Asn Asn Arg Gly Cys Arg 695

Thr Leu Leu Leu Lys Ile Pro Lys Glu Tyr Asp Leu Val Leu Leu Phe 705

Ser Ser Glu Glu Glu Arg Gly Ala Phe Val Gln Gln Leu Trp Asp Phe 730

Cys Val Arg Trp Ala Leu Gly Leu His Val Ala Glu Met Ser Glu Lys

Glu Leu Phe Arg Lys Ala Val Thr Lys Gln Gln Arg Glu Arg Ile Leu 760

Glu Ile Phe Phe Arg His Leu Phe Ala Gln Val Leu Asp Ile Asn Gln 770 775 780

Ala Asp Ala Gly Thr Leu Pro Leu Asp Ser Ser Gln Lys Val Arg Glu
785 790 795 800

Ala Leu Thr Cys Glu Leu Ser Arg Ala Glu Phe Ala Glu Ser Leu Gly 805 810 815

Leu Lys Pro Gln Asp Met Phe Val Glu Ser Met Phe Ser Leu Ala Asp 820 825 830

Lys Asp Gly Asn Gly Tyr Leu Ser Phe Arg Glu Phe Leu Asp Ile Leu 835 840 845

Val Val Phe Met Lys Gly Ser Pro Glu Asp Lys Ser Arg Leu Met Phe 850 855 860

Thr Met Tyr Asp Leu Asp Glu Asn Gly Phe Leu Ser Lys Asp Glu Phe 865 870 875 880

Phe Thr Met Met Arg Ser Phe Ile Glu Ile Ser Asn Asn Cys Leu Ser 885 890 895

Lys Ala Gln Leu Ala Glu Val Val Glu Ser Met Phe Arg Glu Ser Gly 900 905 910

Phe Gln Asp Lys Glu Glu Leu Thr Trp Glu Asp Phe His Phe Met Leu 915 920 925

Arg Asp His Asp Ser Glu Leu Arg Phe Thr Gln Leu Cys Val Lys Gly 930 935 940

Gly Gly Gly Gly Asn Gly Ile Arg Asp Ile Phe. Lys Gln Asn Ile 945 950 955 960

Ser Cys Arg Val Ser Phe Ile Thr Arg Thr Pro Gly Glu Arg Ser His 965 970 975

Pro Gln Gly Leu Gly Pro Pro Val Pro Glu Ala Pro Glu Leu Gly Gly 980 985 990

Pro Gly Leu Lys Lys Arg Phe Gly Lys Lys Ala Ala Val Pro Thr Pro 995 1000 1005

Arg Leu Tyr Thr Glu Ala Leu Gln Glu Lys Met Gln Arg Gly Phe 1010 1020

Leu Ala Gln Lys Leu Gln Gln Tyr Lys Arg Phe Val Glu Asn Tyr 1025 1030 1035

Arg Arg His Ile Val Cys Val Ala Ile Phe Ser Ala Ile Cys Val

1.0

Gly Val Phe Ala Asp Arg Ala Tyr Tyr Tyr Gly Phe Ala Leu Pro 1055 1060 1065

Pro Ser Asp Ile Ala Gln Thr Thr Leu Val Gly Ile Ile Leu Ser 1070 1075 1080

32/61 Arg Gly Thr Ala Ala Ser Val Ser Phe Met Phe Ser Tyr Ile Leu

1090 1095

Leu Thr Met Cys Arg Asn Leu Ile Thr Phe Leu Arg Glu Thr Phe

Leu Asn Arg Tyr Val Pro Phe Asp Ala Ala Val Asp Phe His Arg 1115

Trp Ile Ala Met Ala Ala Val Val Leu Ala Ile Leu His Ser Ala

Gly His Ala Val Asn Val Tyr Ile Phe Ser Val Ser Pro Leu Ser 1145 1150 1155

Leu Leu Ala Cys Ile Phe Pro Asn Val Phe Val Asn Asp Gly Ser

Lys Leu Pro Gln Lys Phe Tyr Trp Phe Phe Gln Thr Val Pro 1175 1180

Gly Met Thr Gly Val Leu Leu Leu Val Leu Ala Ile Met Tyr 1195

Val Phe Ala Ser His His Phe Arg Arg Arg Ser Phe Arg Gly Phe 1205 1210

Trp Leu Thr His His Leu Tyr Ile Leu Leu Tyr Ala Leu Leu Ile

Ile His Gly Ser Tyr Ala Leu Ile Gln Leu Pro Thr Phe His Ile 1235 1245

Tyr Phe Leu Val Pro Ala Ile Ile Tyr Gly Gly Asp Lys Leu Val 1255

Ser Leu Ser Arg Lys Lys Val Glu Ile Ser Val Val Lys Ala Glu 1265 1270 1275

Leu Leu Pro Ser Gly Val Thr Tyr Leu Gln Phe Gln Arg Pro Gln 1285

Gly Phe Glu Tyr Lys Ser Gly Gln Trp Val Arg Ile Ala Cys Leu 1295 1300

Ala Leu Gly Thr Thr Glu Tyr His Pro Phe Thr Leu Thr Ser Ala 1315

Pro His Glu Asp Thr Leu Ser Leu His Ile Arg Ala Val Gly Pro 1325 1330

Trp Thr Thr Arg Leu Arg Glu Ile Tyr Ser Ser Pro Lys Gly Asn 1345

Gly Cys Ala Gly Tyr Pro Lys Leu Tyr Leu Asp Gly Pro Phe Gly 1355 1360 1365

Glu Gly His Gln Glu Trp His Lys Phe Glu Val Ser Val Leu Val 1370 1375

	_													
Gly	Gly 1385	Gly	Ile	Gly	Val	Thr 1390	Pro		33/61 Ala		Ile 1395		Lys	Asp
Leu	Val 1400	Phe	Lys	Ser	Ser	Leu 1405	Gly	Ser	Gln	Met	Leu 1410		Lys	Lys
Ile	Tyr 1415	Phe	Ile	Trp	Val	Thr 1420	Arg	Thr	Gln	Arg	Gln 1425		Glu	Trp
Leu	Ala 1430	Asp	Ile	Ile	Gln	Glu 1435	Val	Glu	Glu	Asn	Asp 1440	His	Gln	Asp
Leu	Val 1445	Ser	Val	His	Ile	Tyr 1450	Val	Thr	Gln	Leu	Ala 1455	Glu	Lys	Phe
Asp	Leu 1460	Arg	Thr	Thr	Met	Leu 1465	Tyr	Ile	Cys	Glu	Arg 1470	His	Phe	Gln
Lys	Val 1475	Leu	Asn	Arg	Ser	Leu 1480	Phe	Thr	Gly	Leu	Arg 1485	Ser	Ile	Thṛ
His	Phe 1490	Gly	Ārg	Pro	Pro	Phe 1495	Glu	Pro	Phe	Phe	Asn 1500	Ser	Leu	Gln
Glu	Val 1505	His	Pro	Gln	Val	Arg 1510	Гуз	Ile	Gly	Val	Phe 1515	Ser	Cys	Gly
Pro	Pro 1520	Gly	Met	Thr	Lys	Asn 1525	Val	Glu	Lys	Ala	Cys 1530	Gln	Leu	Val
Asn	Arg 1535	Gln	Asp	Arg	Ala	His 1540	Phe	Met	His		Tyr 1545	Glu	Asn	Phe

<210> 15 <211> 1676 <212> DNA

<213> Homo sapiens

<400> 15

-100- 10						
agccttatg	, attggattcg	actgaccaaa	agtggaaagg	atctaacggg	attaaaaggc	60
aggttaattg	g aagtaactga	agaagaactt	aagaaacaca	acaaaaaaga	tgattgttgg	120
atatgcataa	gaggtttcgt	ttataatgtc	agcccttata	tggagtatca	tcctggtgga	180
gaagatgaad	taatgagagc	agcaggatca	gatggtactg	aactttttga	tcaggttcat	240
cgttgggtca	attatgaatc	catgctgaaa	gaatgcctgg	ttggcagaat	ggccattaaa	300
cctgctgttc	tgaaagacta	tegtgaggag	gaaaagaaag	tcttaaatgg	catgcttccc	360
aagagccaag	tgacagatac	acttgccaaa	gaaggtccta	gttatccaag	ctatgattgg	420
ttccaaacag	actetttagt	caccattgcc	atatatacta	aacagaagga	tatcaattta	480
gactcaatta	tagttgatca	tcagaatgat	tcctttagag	cagaaacaat	tattaaggat	540
tgtttatatc	ttatacatat	tgggctaagc	catgaggttc	aggaagattt	ttctgtgcgg	600
gttgttgaga	gtgtgggaaa	aatagagatt	gttctacaaa	aaaaagagaa	tacttcttgg	660

gactttettg gecateceet gaagaateat aatteaetta tteeaaggaa agataeaggt	
ttgtactaca gaaagtgcca gttaatttcc aaggaagatg ttactcatga tacgaggctt	
ttctgtttga tgctgccacc aagcactcat cttcaagtgc ccattgggca acatgtttac	
ctcaagctac ctattacagg tacagaaata gtaaagccat atacacctgt atctggttcc	
ttactctcag agttcaagga accagttctt cccaacaata aatacatcta ctttttgata	
aaaatctatc ccactggact cttcacacca gagcttgatc gtcttcagat tggagatttt	
gtttctgtaa gcagtcctga gggcaatttt aaaatatcca agttccaaga attagaagat	
ctctttttgt tggcagctgg aacaggcttc acaccaatgg ttaaaatact gaattatgct	
ttgactgata tacccagtct caggaaagtg aagctgatgt tcttcaataa aacagaagat	
gatataattt ggagaagcca attggagaaa ttagcattta aagataaaag actggatgtt	
gaatttgttc tctcagcacc tatttctgaa tggaatggca aacagggaca tatttcacca	
gctcttcttt ctgaattttt gaaaagaaat ttggacaaat ccaaagttct cgtctgcatt	
tgtggaccag tgccatttac agaacaagga gtaaggttgc tgcatgatct caacttttcc	
aaaaatgaga tecatagttt tacagcataa tgaagagetg teattgteet ttatteaact	
agtttatcta aatttgtgat tgcttagggt tttttaagag aacatttttg tacataacaa	
aaggttaact agaatccagc cttcagtttc ttaaatgaaa tcaaatgttc cttcagtaca	
ggtaacttct tggctttctt ttgtaccaca acttatttta ctactgatat ttgacc	
<210> 16 <211> 487	
<212> PRT	
<213> Homo sapiens	
<pre><400> 16 Met Asp Trp Ile Arg Leu Thr Lys Ser Gly Lys Asp Leu Thr Gly Leu 1</pre>	
1 5 10 15	
Lys Gly Arg Leu Ile Glu Val Thr Glu Glu Glu Leu Lys Lys His Asn 20 25 30	
Lys Lys Asp Asp Cys Trp Ile Cys Ile Arg Gly Phe Val Tyr Asn Val 35 40 45	
Ser Pro Tyr Met Glu Tyr His Pro Gly Gly Glu Asp Glu Leu Met Arg 50 55 60	
Ala Ala Gly Ser Asp Gly Thr Glu Leu Phe Asp Gln Val His Arg Trp 65 70 75 80	
Val Asn Tyr Glu Ser Met Leu Lys Glu Cys Leu Val Gly Arg Met Ala 85 90 95	
Ile Lys Pro Ala Val Leu Lys Asp Tyr Arg Glu Glu Glu Lys Lys Val	

- Leu Asn Gly Met Leu Pro Lys Ser Gln Val Thr Asp Thr Leu Ala Lys
 115 120 125
- Glu Gly Pro Ser Tyr Pro Ser Tyr Asp Trp Phe Gln Thr Asp Ser Leu 130 135 140
- Val Thr Ile Ala Ile Tyr Thr Lys Gln Lys Asp Ile Asn Leu Asp Ser 145 150 155 160
- Ile Ile Val Asp His Gln Asn Asp Ser Phe Arg Ala Glu Thr Ile Ile 165 170 175
- Lys Asp Cys Leu Tyr Leu Ile His Ile Gly Leu Ser His Glu Val Gln
 180 185 190
- Glu Asp Phe Ser Val Arg Val Val Glu Ser Val Gly Lys Ile Glu Ile 195 200 205
- Val Leu Gln Lys Lys Glu Asn Thr Ser Trp Asp Phe Leu Gly His Pro 210 215 220
- Leu Lys Asn His Asn Ser Leu Ile Pro Arg Lys Asp Thr Gly Leu Tyr 225 230 235 240
- Tyr Arg Lys Cys Gln Leu Ile Ser Lys Glu Asp Val Thr His Asp Thr 245 250 255
- Arg Leu Phe Cys Leu Met Leu Pro Pro Ser Thr His Leu Gln Val Pro 260 265 270
- Ile Gly Gln His Val Tyr Leu Lys Leu Pro Ile Thr Gly Thr Glu Ile 275 280 285
- Val Lys Pro Tyr Thr Pro Val Ser Gly Ser Leu Leu Ser Glu Phe Lys 290 295 300
- Glu Pro Val Leu Pro Asn Asn Lys Tyr Ile Tyr Phe Leu Ile Lys Ile 305 310 315 320
- Tyr Pro Thr Gly Leu Phe Thr Pro Glu Leu Asp Arg Leu Gln Ile Gly 325 330 335
- Asp Phe Val Ser Val Ser Ser Pro Glu Gly Asn Phe Lys Ile Ser Lys 340 345 350
- Phe Gln Glu Leu Glu Asp Leu Phe Leu Leu Ala Ala Gly Thr Gly Phe 355 360 365
- Thr Pro Met Val Lys Ile Leu Asn Tyr Ala Leu Thr Asp Ile Pro Ser 370 375 380
- Leu Arg Lys Val Lys Leu Met Phe Phe Asn Lys Thr Glu Asp Asp Ile 385 390 395 400
- Ile Trp Arg Ser Gln Leu Glu Lys Leu Ala Phe Lys Asp Lys Arg Leu 405 410 415
- Asp Val Glu Phe Val Leu Ser Ala Pro Ile Ser Glu Trp Asn Gly Lys
 420 425 430

WO 03/087399 PCT/SE03/00618 36/61

Gln Gly His Ile Ser Pro Ala Leu Leu Ser Glu Phe Leu Lys Arg Asn

Leu Asp Lys Ser Lys Val Leu Val Cys Ile Cys Gly Pro Val Pro Phe 450

Thr Glu Gln Gly Val Arg Leu Leu His Asp Leu Asn Phe Ser Lys Asn

Glu Ile His Ser Phe Thr Ala

<210> 17

<211> 1340

DNA

<213> Homo sapiens

<400> 17

::.

ccacccagtc atgggggaca cettcatccg tcacatcgcc ctgctgggct ttgagaagcg 60 cttcgtaccc agccagcact atgtgtacat gttcctggtg aaatggcagg acctgtcgga 120 gaaggtggtc taccggcgct tcaccgagat ctacgagttc cataaaacct taaaagaaat 180 gttccctatt gaggcagggg cgatcaatcc agagaacagg atcatccccc acctcccagc 240 teccaagtgg tttgacggge agegggeege cgagaacege cagggeacac ttaccgagta 300 ctgcagcacg ctcatgagcc tgcccaccaa gatctcccgc tgtccccacc tcctcgactt 360 cttcaaggtg cgccctgatg acctcaagct ccccacggac aaccagacaa aaaagccaga 420 gacatacttg atgeccaaag atggcaagag tacegegaca gacateaceg gecceateat 480 cctgcagacg taccgcgcca ttgccgacta cgagaagacc tcgggctccg agatggctct 540 gtccacgggg gacgtggtgg aggtcgtgga gaagagcgag agcggttggt ggttctgtca 600 gatgaaagca aagcgaggct ggatcccagc atccttcctc gagcccctgg acagtcctga 660 cgagacggaa gaccctgagc ccaactatgc aggtgagcca tacgtcgcca tcaaggccta 720 cactgetgtg gagggggacg aggtgteeet getegagggt gaagetgttg aggteattea 780 caagerectg gaeggetggt gggteateag gaaagaegae gteacagget acttteegte 840 catgtacctg caaaagtcgg ggcaagacgt gtcccaggcc caacgccaga tcaagcgggg 900 ggcgccgccc cgcaggtcgt ccatccgcaa cgcgcacagc atccatcagc ggtcgcggaa 960 gegecteage caggaegeet ategeegeaa cagegteegt tttetgeage agegaegeeg 1020 ccaggegegg cegggacege agageeeegg gageeegete gaggaggage ggcagaegea 1080 gcgctctaaa ccgcagccgg cggtgccccc gcggccgagc gccgacctca tcctgaaccg 1140 ctgcagcgag agcaccaagc ggaagctggc gtctgccgtc tgaggctgga gcgcagtccc 1200 cagctagegt cteggeeett geegeeeegt geetgtacat aegtgtteta tagageetgg 1260 cgtctggacg ccgagggcag ccccgacccc tgtccagcgc ggctcccgcc accctcaata 1320

1340

aatgttgctt ggagtggaag

<210> 18 <211> 390

<212> PRT

<213> Homo sapiens

<400> 18

Met Gly Asp Thr Phe Ile Arg His Ile Ala Leu Leu Gly Phe Glu Lys

1 10 15

Arg Phe Val Pro Ser Gln His Tyr Val Tyr Met Phe Leu Val Lys Trp
20 25 30

Gln Asp Leu Ser Glu Lys Val Val Tyr Arg Arg Phe Thr Glu Ile Tyr
35 40 45

Glu Phe His Lys Thr Leu Lys Glu Met Phe Pro Ile Glu Ala Gly Ala 50 55 60

Ile Asn Pro Glu Asn Arg Ile Ile Pro His Leu Pro Ala Pro Lys Trp 70 75 80

Phe Asp Gly Gln Arg Ala Ala Glu Asn Arg Gln Gly Thr Leu Thr Glu 85 90 95

Tyr Cys Ser Thr Leu Met Ser Leu Pro Thr Lys Ile Ser Arg Cys Pro 100 105 110

His Leu Leu Asp Phe Phe Lys Val Arg Pro Asp Asp Leu Lys Leu Pro 115 120 125

Thr Asp Asn Gln Thr Lys Lys Pro Glu Thr Tyr Leu Met Pro Lys Asp 130 135 140

Gly Lys Ser Thr Ala Thr Asp Ile Thr Gly Pro Ile Ile Leu Gln Thr 145 150 155 160

Tyr Arg Ala Ile Ala Asp Tyr Glu Lys Thr Ser Gly Ser Glu Met Ala 165 170 175

Leu Ser Thr Gly Asp Val Val Glu Val Glu Lys Ser Glu Ser Gly
180 185 190

Trp Trp Phe Cys Gln Met Lys Ala Lys Arg Gly Trp Ile Pro Ala Ser 195 200 205

Phe Leu Glu Pro Leu Asp Ser Pro Asp Glu Thr Glu Asp Pro Glu Pro 210 215 220

Asn Tyr Ala Gly Glu Pro Tyr Val Ala Ile Lys Ala Tyr Thr Ala Val 225 230 235 240

Glu Gly Asp Glu Val Ser Leu Leu Glu Gly Glu Ala Val Glu Val Ile
245 250 255

His Lys Leu Asp Gly Trp Trp Val Ile Arg Lys Asp Asp Val Thr 260 . 265 270

WO 03/087399 PCT/SE03/00618

38/61 Gly Tyr Phe Pro Ser Met Tyr Leu Gln Lys Ser Gly Gln Asp Val Ser 280 Gln Ala Gln Arg Gln Ile Lys Arg Gly Ala Pro Pro Arg Arg Ser Ser Ile Arg Asn Ala His Ser Ile His Gln Arg Ser Arg Lys Arg Leu Ser 310 Gln Asp Ala Tyr Arg Arg Asn Ser Val Arg Phe Leu Gln Gln Arg Arg 325 330 Arg Gln Ala Arg Pro Gly Pro Gln Ser Pro Gly Ser Pro Leu Glu Glu Glu Arg Gln Thr Gln Arg Ser Lys Pro Gln Pro Ala Val Pro Pro Arg 360 Pro Ser Ala Asp Leu Ile Leu Asn Arg Cys Ser Glu Ser Thr Lys Arg Lys Leu Ala Ser Ala Val 385 <210> 19 <211> 2206 <212> DNA Homo sapiens <213> <400> 19 ctagtctttc agcettcagg ctgtttttgg cttgaagctc tcttggcctc ctagtttcta 60 cctaatcatg tccctggtgg aggccatcag cctctggaat gaaggggtgc tggcagcgga 120 caagaaggac tggaagggag ccctggatgc cttcagtgcc gtccaggacc cccactcccg 180 gatttgcttc aacattggct gcatgtacac tatcctgaag aacatgactg aagcagagaa 240 ggcctttacc agaagcatta accgagacaa gcacttggca gtggcttact tccaacgagg 300 gatgctctac taccagacag agaaatatga tttggctatc aaagacctta aagaagcctt 360 gattcagett egagggaace agetgataga etataagate etggggetee agttcaaget 420 gtttgcctgt gaggtgttat ataacattgc tttcatgtat gccaagaagg aggaatggaa 480 aaaagctgaa gaacagttag cattggccac gagcatgaag tctgagccca gacattccaa 540 aatcgacaag gcgatggagt gtgtctggaa gcagaagcta tatgagccag tggtgatccc 600 tgtgggcaag ctgtttcgac caaatgagag acaagtggct cagctggcca agaaggatta 660 cctaggcaag gcgacggtcg tggcatctgt ggtggatcaa gacagtttct ctgggtttgc 720 ccctctgcaa ccacaggcag ctgagcctcc acccagaccg aaaaccccag agatcttcag 780 ggctctggaa ggggaggctc accgtgtgct atttgggttt gtgcctgaga caaaagaaga 840 gctccaggtc atgccaggga acattgtctt tgtcttgaag aagggcaatg ataactgggc 900

cacggtcatg ttcaacgggc agaaggggct tgttccctgc aactaccttg aaccagttga

960

gttgcggatc	caccctcagc	agcagcccca	ggaggaaagc	tctccgcagt	ccgacatccc	1020
agctcctcct	agttccaaag	cccctggaaa	accccagctg	tcaccaggcc	agaaacaaaa	1080
agaagagcct	aaggaagtga	agctcagtgt	tcccatgccc	tacacactca	aggtgcacta	1140
caagtacacg	gtagtcatga	agactcagcc	cgggctcccc	tacagccagg	tccgggacat	1200
ggtgtctaag	aaactggagc	tccggctgga	acacactaag	ctgagetate	ggcctcggga	1260
cagcaatgag	ctggtgcccc	tttcagaaga	cagcatgaag	gatgcctggg	gccaggtgaa	1320
aaactactgc	ctgactctgt	ggtgtgagaa	cacagtgggt	gaccaaggct	ttccagatga	1380
acccaaggaa	agtgaaaaag	ctgatgctaa	taaccagaca	acagaacctc	agcttaagaa	1440
aggcagccaa	gtggaggcac	tcttcagtta	tgaggctacc	caaccagagg	acctggagtt	1500
tcaggaaggg	gatataatcc	tggtgttatc	aaaggtgaat	gaagaatggc	tggaagggga	1560
gtgcaaaggg	aaggtgggca	ttttccccaa	agtttttgtt	gaagactgcg	caactacaga	1620
tttggaaagc	actcggagag	aagtctagga	tgtttcacaa	actacaaagc	tgaagaaaat	1680
gaagccctat	tacttgtttg	taagatttag	cacccttctg	ctgtatactg	tactgagaca	1740
ttacagtttg	gaagtgttaa	ctatttattc	cctgttaaaa	tttaacctac	tagacaatga	1800
tgtgagtacc	caggatgatt	tectggggca	cagtgggtga	ggagatgggg	acaggtgaat	1860
ggaggagtta	ggggagagga	aaagtggatg	gaagtgtctg	gaaagggcac	gagagagtct	1920
tccaggtact	gatcctgttt	cttgctctga	gtgctagcta	gccagctgtg	ttcacactgt	1980
aaacattcat	caagctgtac	atttggtgca	cttttctgtg	tcataccaca	ataaaaaaaa	2040
acctatcatc	atcttacaaa	aacaagacac	ccaagtccag	gcccaaggag	taagtacaaa	2100
tattcctgtt	tctgaaccat	tactgtaatt	ggctcttaag	gcttgaagta	accttatagg	2160
ttactcataa	ggcatataca	aataaacttg	tttgttttct	ttttc		2206

<210> 20

<211> 526

<212> PRT

<213> Homo sapiens

<400> 20

Met Ser Leu Val Glu Ala Ile Ser Leu Trp Asn Glu Gly Val Leu Ala 1 5 10 15

Ala Asp Lys Lys Asp Trp Lys Gly Ala Leu Asp Ala Phe Ser Ala Val 20 25 30

Gln Asp Pro His Ser Arg Ile Cys Phe Asn Ile Gly Cys Met Tyr Thr
35 40 45

Ile Leu Lys Asn Met Thr Glu Ala Glu Lys Ala Phe Thr Arg Ser Ile 50 55 60

Asn Arg Asp Lys His Leu Ala Val Ala Tyr Phe Gln Arg Gly Met Leu

Tyr Tyr Gln Thr Glu Lys Tyr Asp Leu Ala Ile Lys Asp Leu Lys Glu

Ala Leu Ile Gln Leu Arg Gly Asn Gln Leu Ile Asp Tyr Lys Ile Leu

Gly Leu Gln Phe Lys Leu Phe Ala Cys Glu Val Leu Tyr Asn Ile Ala

Phe Met Tyr Ala Lys Lys Glu Glu Trp Lys Lys Ala Glu Glu Gln Leu

Ala Leu Ala Thr Ser Met Lys Ser Glu Pro Arg His Ser Lys Ile Asp

Lys Ala Met Glu Cys Val Trp Lys Gln Lys Leu Tyr Glu Pro Val Val

Ile Pro Val Gly Lys Leu Phe Arg Pro Asn Glu Arg Gln Val Ala Gln 185

Leu Ala Lys Lys Asp Tyr Leu Gly Lys Ala Thr Val Val Ala Ser Val

Val Asp Gln Asp Ser Phe Ser Gly Phe Ala Pro Leu Gln Pro Gln Ala

Ala Glu Pro Pro Pro Arg Pro Lys Thr Pro Glu Ile Phe Arg Ala Leu 230 235

Glu Gly Glu Ala His Arg Val Leu Phe Gly Phe Val Pro Glu Thr Lys 250

Glu Glu Leu Gln Val Met Pro Gly Asn Ile Val Phe Val Leu Lys Lys

Gly Asn Asp Asn Trp Ala Thr Val Met Phe Asn Gly Gln Lys Gly Leu 280

Val Pro Cys Asn Tyr Leu Glu Pro Val Glu Leu Arg Ile His Pro Gln 295

Gln Gln Pro Gln Glu Glu Ser Ser Pro Gln Ser Asp Ile Pro Ala Pro 310 315

Pro Ser Ser Lys Ala Pro Gly Lys Pro Gln Leu Ser Pro Gly Gln Lys

Gln Lys Glu Glu Pro Lys Glu Val Lys Leu Ser Val Pro Met Pro Tyr 345

Thr Leu Lys Val His Tyr Lys Tyr Thr Val Val Met Lys Thr Gln Pro

Gly Leu Pro Tyr Ser Gln Val Arg Asp Met Val Ser Lys Leu Glu

41/61 Leu Arg Leu Glu His Thr Lys Leu Ser Tyr Arg Pro Arg Asp Ser Asn Glu Leu Val Pro Leu Ser Glu Asp Ser Met Lys Asp Ala Trp Gly Gln 410 Val Lys Asn Tyr Cys Leu Thr Leu Trp Cys Glu Asn Thr Val Gly Asp Gln Gly Phe Pro Asp Glu Pro Lys Glu Ser Glu Lys Ala Asp Ala Asn Asn Gln Thr Thr Glu Pro Gln Leu Lys Lys Gly Ser Gln Val Glu Ala Leu Phe Ser Tyr Glu Ala Thr Gln Pro Glu Asp Leu Glu Phe Gln Glu Gly Asp Ile Ile Leu Val Leu Ser Lys Val Asn Glu Glu Trp Leu Glu Gly Glu Cys Lys Gly Lys Val Gly Ile Phe Pro Lys Val Phe Val Glu Asp Cys Ala Thr Thr Asp Leu Glu Ser Thr Arg Arg Glu Val <210> 21 <211> 1301 <212> DNA Homo sapiens <213> <400> 21 agacteteca eetgeteeet gggaceateg eecaceatgg etgtggeeea geagetgegg 60 geegagagtg aetttgaaca getteeggat gatgttgeea teteggeeaa cattgetgae 120 atcgaggaga agagaggett caccagecae tttgtttteg teatcgaggt gaagacaaaa 180 ggaggatcca agtacctcat ctaccgccgc taccgccagt tccatgcttt gcagagcaag 240 ctggaggagc gcttcgggcc agacagcaag agcagtgccc tggcctgtac cctgcccaca 300 ctcccagcca aagtctacgt gggtgtgaaa caggagatcg ccgagatgcg gatacctgcc 360 ctcaacgcct acatgaagag cctgctcagc ctgccggtct gggtgctgat ggatgaggac 420 gteeggatet tettttaeea gtegeeetat gaeteagage aggtgeeeea ggeaeteege 480 eggeteegee egegeaceeg gaaagteaag agegtgteee cacagggeaa cagegttgae 540 cgcatggcag ctccgagagc agaggctcta tttgacttca ctggaaacag caaactggag 600 ctgaatttca aagctggaga tgtgatcttc ctcctcagtc ggatcaacaa agactggctg 660 gagggcactg teeggggage caegggeate tteeetete cettegtgaa gateeteaaa 720 gacttccctg aggaggacga ccccaccaac tggctgcgtt gctactacta cgaagacacc 780

atcagcacca tcaagtctgt ggcctgggag ggaggggcct gtccagcctt cctgccatcc

840

ctacgaccac	cgcccctcac	atcaccttct	catgggtccc	tctcccactc	caaagccccc	900
agtggctccc	agatgagcca	caatgctgta	acaagccatc	aacgtccagg	gtggcctggc	960
cagcctcatt	cccctttccc	ccaccccaca	ccccacttcc	agcctgatgc	ctccttactc	1020
cagcctgtca	ccccttagg	gacategegg	tggaggaaga	tctcagcagc	actcccctat	1080
tgaaagacct	gctggagctc	acaaggcggg	agttccagag	agaggacata	gctctgaatt	1140
accgggacgc	tgagggggat	ctggttcggc	tgctgtcgga	tgaggacgta	gcgctcatgg	1200
tgcggcaggc	tcgtggcctc	ccctcccaga	agcgcctctt	cccctggaag	ctgcacatca	1260
cgcagaagga	caactacagg	gtctacaaca	cgatgccatg	a		1301

<210> 22

<211> 348

<212> PRT

<213> Homo sapiens

<400> 22

Met Ala Val Ala Gln Gln Leu Arg Ala Glu Ser Asp Phe Glu Gln Leu 1 5 10 15

Pro Asp Asp Val Ala Ile Ser Ala Asn Ile Ala Asp Ile Glu Glu Lys 20 25 30

Arg Gly Phe Thr Ser His Phe Val Phe Val Ile Glu Val Lys Thr Lys 35 40 45

Gly Gly Ser Lys Tyr Leu Ile Tyr Arg Arg Tyr Arg Gln Phe His Ala 50 55 60

Leu Gln Ser Lys Leu Glu Glu Arg Phe Gly Pro Asp Ser Lys Ser Ser 65 70 75 80

Ala Leu Ala Cys Thr Leu Pro Thr Leu Pro Ala Lys Val Tyr Val Gly 85 90 95

Val Lys Gln Glu Ile Ala Glu Met Arg Ile Pro Ala Leu Asn Ala Tyr 100 105 110

Met Lys Ser Leu Leu Ser Leu Pro Val Trp Val Leu Met Asp Glu Asp 115 120 125

Val Arg Ile Phe Phe Tyr Gln Ser Pro Tyr Asp Ser Glu Gln Val Pro 130 135 140

Gln Ala Leu Arg Arg Leu Arg Pro Arg Thr Arg Lys Val Lys Ser Val 145 150 155 160

Ser Pro Gln Gly Asn Ser Val Asp Arg Met Ala Ala Pro Arg Ala Glu 165 170 175

Ala Leu Phe Asp Phe Thr Gly Asn Ser Lys Leu Glu Leu Asn Phe Lys
180 185 190

Ala Gly Asp Val Ile Phe Leu Leu Ser Arg Ile Asn Lys Asp Trp Leu 195 200 205

43/61 Glu Gly Thr Val Arg Gly Ala Thr Gly Ile Phe Pro Leu Ser Phe Val 215 Lys Ile Leu Lys Asp Phe Pro Glu Glu Asp Asp Pro Thr Asn Trp Leu 230 235 Arg Cys Tyr Tyr Tyr Glu Asp Thr Ile Ser Thr Ile Lys Ser Val Ala 245 Trp Glu Gly Gly Ala Cys Pro Ala Phe Leu Pro Ser Leu Arg Pro Pro Pro Leu Thr Ser Pro Ser His Gly Ser Leu Ser His Ser Lys Ala Pro 275 280 285 Ser Gly Ser Gln Met Ser His Asn Ala Val Thr Ser His Gln Arg Pro 295 Gly Trp Pro Gly Gln Pro His Ser Pro Phe Pro His Pro Thr Pro His 315 Phe Gln Pro Asp Ala Ser Leu Leu Gln Pro Val Thr Pro Leu Gly Thr 325 330 Ser Arg Trp Arg Lys Ile Ser Ala Ala Leu Pro Tyr <210> 23 28567 <212> DNA <213> Homo sapiens

<211>

<400> 23 gtttcaccat gttggtgagg ctggtctcaa actcctgaac ttgtgatcca cccacctggg 60 ccgcccaacc aaagtgctgg gatgacagac gtgagccact gcgcccagcc accacaggtt 120 cctctttttt tttttttt ttgagacggg gtctcgctct gactccaggc tggagtgcag 180 tggcgccatc tgggctcact gaaaccaccg ceteccaggt tcaagagatt etectgeete 240 aggeteetga gtagetggaa etaeaggege gegeeteeae geeetgetaa tetaatttt 300 gtatttttag tagagacggg gtttcaccat gttggccagg atggtctcga tctcttgacc 360 ttgtgatecg ccctcctcgg cctcccaaag tgctgggttt acaggcttga gccaccgcgc 420 cotgtctgac aggttcctcg tttttgtttt tgttttttt tttgagacgg agtttcgctc 480 ttgtcgccca ggctggagtg caatagcagg atctcggctc actgcaacca ctgcctcccg 540 ggttgaagtg attcacctgc ctcagcctcc tgagtagctg ggattacagg cgcccaccac 600 cacgccccgt taattttttg tatttttatt agagacagtg tttcaccatg ttggccaggc 660 tggtcttgaa ctcgtgacct caggtgatcc gcccgcctca gcctcccaaa gtgttgggat 720 tacggacgtg agccaccgcg ccgagetgac aggttcetet taaagccetg agteccaggg 780 aagggacetg caggeeegge caegeeeagg eegetttage gegeaagatg geggeatgea 840

attagagtat gtaggctatt caggcttttt ttttttttt tttttttg agacggagtt

2700

Frank.

tcactctgtt gcccaggctg gagtgcagtg gcacgatttc ggctcactac aacctccgcc 2760 teccaggite aagegateet cetgeeteag tgteettagt agetgggatt acaggeaege 2820 gccaccgtgt ccggctaatt tttgtatttt ttagtagaga cggggtttca ccatgttggc 2880 ctggctggtc tcgaattcct gacctcaggt gatccacccg cctgggtctc ccagagtgtt 2940 gggattacag gcgtaagcca cggcgcccgg cccaattttt ttttttttc ttttctttt 3000 ttttttttg agacggggtc tcactctgtc gcccaggctg gagtgcaatg gcgcgatctc 3060 tgctcctgca acctctgcct cccgggttca agcgattctc gtgccttagt ctcccaagta 3120 gctgggatta caggcgcaag ccaccatgcc cagctaattt gtttttttt ttttttttg 3180 tatttttttg gtggagacgg agtttcacca tgttggtgag gctggtctca aactcctgac 3240 cctcaagtga tccgcccgcc tcggcctgtt ttttttttt ttttttta agtcatattg 3300 ctgataatta tttgaaaatt tctaaaacta aaacataagc atagcagata cgtttattta 3360 atactaaccg attgtggacc tctgctgttt gaattggctg ttttatctag tcaaataact 3420 tgttgaatgt catggaatct ggaccgtccc ttcaaatccc caccccaccg cttacatggg 3480 gtaaccctaa gcacatcccc cacctcccaa gagaggcggt tcaatgggag gtcaacaaga 3540 ctaaacaaga tgttggttat taactacctc gcaggtgccc cttgctgaat gcttagtaaa 3600 tgccaggtac tgttattgcg gtttctacta ctgagactct gtgagggagt attaggctta 3660 aaagtctgtg gccttgagtt ttcagtctgt ttttttttt taattagtta tgagcatttg 3720 aacaagcaca gttattttt aatactatgt ttagtattga tgttgactac agctaagtga 3780 tattagaagt gaaatgtacc tggccaggtc aggtggctca cacctgtaac ccagcatttt 3840 gggaggccaa ggtgggtgga tcactagagc ttaggagttc aagaccagcc tgggcaacat 3900 ggcgagacce tgtctctgct aaaaatacaa aaattagcta ggtgtagaca catgtgcctg 3960 tagtcccagc tactcgggag gctaaggtgg gaggatcgct tgaaacccag gaggtggagg 4020 ttgtagtgag ctgagattgt gccattgcac tccagcccgt gcgacagagt gagaccttgt 4080 ctcaaaaaag caaaaacaaa aactattaga gatacgtctt tggccgggca cggtagctca 4140 agcctgtaat cccagcactt tgggaggccg aggtgggcgg ttcacctgag gtcaggagtt 4200 tgagaccagt ctggccaata tggcgaaacc tcgtctctac taaaaataga aaaattagct 4260 gggcacgcct gtaatcctag ctattcagga ggttgaggca ggagaatcgc ttgaacttgg 4320 gaggtggagg ttgcagtgag ccaagattgt accattgcac tccagcttgg gtgacagagg 4380 gaaactgtct ttttttgttt gtttgttttt aaaggagata catcttcatc tgttcctgct 4440 ttgaccettt geetggacca tggcagtgte ettteagget gtacgteect ecateetgee 4500

gatatgggct catggcaacc tetgcetect gggttcaage agtteteetg etttggeete

6360

ccaaagtgat ggaattacag gcccgagcca ctgcgcccgg ccacaactat tttaatagtg 6420 ttgttttggt gttggttgat taaaggaatg ggaacgaatg acttgaagcc ctctctgttt 6480 cactetttat acaaagtgga gtccagattg ggctagtggc ctgtctagcc caatgtctga 6540 cttggacata cattactgtc caggagtttc ttagctgaat gtgaaaaatg ccttccgtga 6600 catcatcctt acaggaacat tctttacatt tattctttac ttctgttgaa cggtggtggc 6660 gtgaaccatg aatttgttta agcttttcag ctgttttgtg tgttttcctc tcaaggcatg 6720 gggtttcata tttttgacct gtggtaaagg tatttgaatt ctgcactggc ctccaaatgt 6780 aggtgtagta tatggctctg atcittgttg atgattttat acataatgtg gtttttttc 6840 ttgataagcc aaaaaaatta tacataatgt gtgtgtgtgt gtgtgtttta atttcaaatg 6900 atagttacag taaaagtttg gagttgggct aagtgggagg agcatcagga agccatttt 6960 agaaacctta aattcaccct ttataacttt ctgtcttttt gcattagtca tctgatacct 7020 tagtactgcc tactttttca catctccatc actacgtagc tcttaaaatt gtagtcttcc 7080 ttgaaaggag atgtttttgt caagagtctt tgccaccaag gcaggattgc atgtgatcag 7140 taggaatatt ttcctgcaat gtcttaatat gaaaaatttc aaacagacta gtggaaagca 7200 ttgtacagtc aacatgcaca tacccatggc ctggattcta tgacagtatt ttgctctact 7260 tgttcatttt gctgtatttg ctttatcatg tcttcctgtt atcagaggga accttttaag 7320 aggatttata gaggagttga ttttgttttt tgttttgttt tgttttgctc tttttgaggt 7380 ggagtcttgc tctgttgccc aggetggagt gcaatggcat gatctctgct cactgcaatc 7440 tecgeatece aggtteagge gattetectg ceteageete etgagtaget gggettacag 7500 gcacccacca ccatgcctgg ctaatttttg tattcttagt tgagacaggt ttcaccatct 7560 tggccagget ggtctggaac tectgacete aggtgateca eetgeetegg eeteccaaag 7620 tgatgggatt acaggcgtca gccaccatgc ccggcctgat tttgaaaaag aatagggact 7680 gtgtgcagtt acatataaat tcttattttt gaactcttgt gtgttcagct ggcttgtatc 7740 aactacacca gggttagcct tgattctgga agggtggatt cagacttcag ctcagttgta 7800 catagtgtct tcagcctaag tgagaaactt tatgcactat cttaattttt tgaagcttct 7860 agtggtaata attgctggct ttttttttt ttttttggta gaaacagagt cttgctctgt 7920 cgccaggctg gagtgcagtg gcacgaaatc agctcactgc aacctctgcc tcccaggttc 7980 aagcaattet eetgeeteag eeteetgagt agetgagatt acaggegtgt gecaccacae 8040 ccagctaatt tetttgtat tttagtagag acggggtttc actgtgctgc ccaggctggt 8100 cttgaactcc taaggtcaga cagtccgccc accttgccct cctaaagtgc taggattaca 8160

gacatagatt tgtaacaaat agtgattggt aataaaattt cagtcagtat cagattatgc

10020

cagtaccttg aatttcttcc cggttgagcc tttctcagct aaagatgtca ttcaggaaag gaagtttaga ggattttaga cacagctggt tgcctttata ttagtagttt tgttcctcat 10140 atacatagag acttaggaca gaatagtaaa agaagtgata atgacatttt atcataacag 10200 tcaaaacctt catagcagct tatccttgac actgagtggc aactattgtt aaggttttta 10260 10320 tgctcttgtt gcccaggctg gagtgcaatg gcgcaatctc ggctcactgc aacttccgcc 10380 tecegggtte aagegaetet cetgetteag cetecegagt agetgggatt acaggeatge 10440 acgcccggct aattttgtat ttttagtaga gaggggtttc tccatgttgg tcaggctctt 10500 ctegaattee tgaceteagg tgateegeee geettggeet eecaaagtge tgggattaca 10560 tgtgtgagcc accgagccca gccaaccttt atcattttta aaaaggtccc ttagagcctt 10620 aggetecaet tretteetea getgecaeat ceaaaceatg ggtaagegat gettgatetg 10680 cctccaagtt caagcagtcc aggaaacagc ccacttatgt tcactgtcca gtccccattc 10740 ttggtccagg ccaccatgga tggctcctgg actgtagcaa cagcttccat gtgtgtctgc 10800 cttgactgag tccctggcgt cctcaggctt cctgccacac tgcagttgga ggcttcttct 10860 aaaatccagt gctttctggg caatttaaaa cctgtgactt tccaagtagg atctagtccc 10920 catgtcctta acaagaagag gtaacgtatt teectatgee actgeecact tatttttta 10980 ttgttgagat gggatcgtgc tttgtcacct aggctgggtg gagtggtgtg atcacagctc 11040 actgctgccc tgaattcctg ggctgaaggg atcctcttgc ttcagcctcc tgagtagctg 11100 ggactacagg caagagccac cacttatttt tgaatttttt gtggaaacaa ggtctcccta 11160 tgttgcccag gctggtcttg aactcctggg ctcagcgatc ctcccacctc aggcccctgt 11220 gctgggatta tagcctcctg tgctgggatt acaggcctaa gccactgcac caggctttta 11280 ttttttaatt taaaaaaatt tattttttg agacagggtc tcactttgtc cctcagactg 11340 gatgcactgg tgcaatcttg tttcactgca gccttgacct ccctcctggg ttcaagtgat 11400 cctcgtgcct cagcccccca agtagctgag actactgctg cacaccgcca cacccaccta 11460 atttttgtat ttttagtaga gaacgggttt ctccatgttg gcccagctgg tcttgaactc 11520 ctgggctcaa gcgatccacc cacctcagcc tcccaaagtg ctaggattac aggcatgagc 11580 caccatgcct ggcctaaaaa tattttttc agctctagaa atgttagctc ttttgctgta 11640 catttccaga gctgctttaa taatgacagt tatcacacgc ataatttcat gtgatgattg 11700 cattcttaat ttttaaattt aacaactgca cttacttcat gaggtcttgt tcattgatac 11760 atctttagca cctagtgtgc ttctggtgta gcacacggtt gatataaatt gaaattgaat 11820

			50/61			
taatgctcac	agtagtttgg	ggatggagct	ggtagttctg	cattaattt	gcaggtgaaa	11880
aaaaaaggca	tgaggaagtt	gaaacttgcc	aaaaaataca	gccagtacgt	gctagaattg	11940
gccctgggtc	tcaaatctgg	gcttctgact	ccaaagctta	ggctcctgct	catacaggtt	12000
tattttcaca	ttctaagctt	ttaacgaaat	gtatgtccaa	tgagtcattt	ctgtttagaa	12060
agcctttagg	agttggaagc	tacttcctgg	tgatgtaatg	tttgactctc	taaagtcttt	12120
ggaatgggga	gttccaactt	ttgttaagcc	ctcaataatg	tcatgagtga	atgaatattg	12180
gcaagactgg	ctgggcctgt	aatctgcctt	gagtgtgagg	gaaaatggaa	aagcgcttaa	12240
ctttatggtg	aattctaatt	tatagtagtt	gagattgaac	gacaaaaatc	ttaaaattat	12300
gatgctgatg	tgtcattgtg	accttggtaa	actgacagca	cagcagagag	aagggctcat	12360
taaggagagc	acttggctaa	ctgaaccctc	aggatgccag	agacttgaat	tctcatgtaa	12420
gcccttaagc	ttgccttgtc	aatgctgtaa	aaattggaga	cctttatgtt	ttgctaatga	12480
tgtggtgacc	ttagttatta	ggtgatagcc	tcttgaaaaa	cattccaggt	ggttgggaga	12540
ctttcagcca	ccáctcttct	geetggegge	acactggtaa	tattaggatt	agtctctacc	12600
cattgccagt	tgtgcaggtg	gtgctccttt	ctctgaagta	tttctacaca	cttctctgtt	12660
tggcaagttt	aactcccatc	gtctctgagc	tgţtaattaa	atgtctggga	tgtattgtga	12720
tagtccctgc	ttatagactt	atggtgctgt	gtgaggattg	gggctggggg	aggtggcatt	12780
taaatacagc	tgaatcaatg	tgatggcagt	tacgtgtggt	agtttattga	ctaagcactt	12840
tctctcaaga	gaacagtcat	tgctgattgc	cataggggag	gctgtaggga	tgtggtggga	12900
ttttgagctg	tcccacttaa	ggcagcagaa	taagttactt	aaagaggaag	gctgtgtttg	12960
tatattagtg	ttaattaaaa	tacctttagg	ctgggtgtgg	tggctccagc	ctgtaatccc	13020
agcactttgg	gaggtccagg	tgggcggatc	acttgaggtc	aggagttcga	gaccagcctg	13080
gccaacatgg	cgaaaaccca	tctctactaa	aaatacaaaa	aaattatcca	ggcgtggtgg	13140
tggacagetg	taatcccagc	tacttgggag	gctgaggcag	gagaatcgct	tgaacctggg	13200
aggcagaggt	tgcagtgagc	caagatggtg	cctctgcact	gcactccagc	tggggcgaca	13260
gcacgagact	cggtctcaaa	aaaaaaaaa	aaagaaaaaa	aagaaaaaaa	gaaaatatct	13320
tcaggatcaa	acttaagatt	cttgatgaga	ggctctacag	atgttcacag	aagagacgtg	13380
aagttttaaa a	atcttgtttc	tettgagtet	tgtagctagg	tgacaactgt	ttcttgacta	13440
ttaatgctaa	caccgggtac	ctaaacagaa	tgtgatggct	cctgactcta	tctttctgag	13500
aaattctagt (ttgtttactt	taaatttcag	ggtaccaatg	tgtatgtggt	gataaagggt	13560
tatagaaaac a	attttcttta	atgctaagta	tgtgatgtat	atgccttgat	tttttttctc	13620
tagaaattat (tttaacttaa	tagtgaaagc	taagattaca	ttcatgttga	ctaagcaacc	13680

ttttttctct ttctctttag agctgtaggt aaaacttgcc tactgatcag ttacacaacc aatgcatttc ctggagaata tatccctact gtgtaagtat cttaaattgg gaattaacct 13800 gtttgtgtta cgggtttcac atttctttga ccatttgttt tgctgtaaag ccatctttaa 13860 tcctcatatg aacagatact aattttttct taaacattca ctgaaaccta attataaggt 13920 atattaggct tttaaaaaat agggctgggg gtggtgatct cagcactttg ggagactgag 13980 gcgggtggat caactgaggg tcaggagttc gagaccagca tggtcaacgt gatgaaaccc 14040 catctctact aaaaatacaa aaaattagcc aggtgtggtg gcgggtgcct gtaatcccac 14100 atacttggga ggctgaggca ggagaatcac tcgaaccgtg gaggcggagg ttgcagtgag 14160 ccaagatcac gccactgcac tccagcctgg gcaatgagag cgaaactcca tctcaaaaga 14220 aaaaaaaaaa agaaacttag ggtaatataa acttttcaca actttgctag ttgattttta 14280 gacatccaga aagcaaactt taactgtctg tgaggtacag agactggatg atgttaaaga 14340 aaaccatagt tggacacaag aactctgacc aaaagtctga tcagaaacag tccttgtcag 14400 tgcacgagtt tcagatacac tggctttctg ggaactggaa agggaaagat tccattacgt 14460 tttaattggc cttttctgat aagtcatcag ttggttacat gtccgcattg aggtgtaggg 14520 ctttggaatt gaaacttggg tgtgtgttt gaagggggaa tgggagggtg gaattggcta 14580 ttgaattgct tactccctat aggcagcaga attgggtgga gacaggaaag tgctgctctg 14640 gtgatgggtt accegggage geaegtaget gageeteata atgeaecate etgeagetge 14700 tgtgagtcct ccctgtgcag gctggggagg tgtcgcctcc tccccacctg tgttcacctc 14760 ctcaggcaca acacacacc aggtgctctc tgaagtgtcg tacccatgtt tttgttgttg 14820 ttgttgttgt tttccttttt tttttttt tttggagtta gtctctctc cttgcccagg 14880 atggagtget gtgatgegat eteageteac tgeagegtet geeteetggg tteaagtgat 14940 tetetgeete ageeteecag gtagetgtga ttacaggeat acaccaccae acetggetaa 15000 tttttgtttc tttagtagag acgggtttca ccatgttggc caggttggtc tcaaactcct 15060 gacctcaggt gatctgccca cttcagcctc ccaaagtgct gggattacag gcgtgagcca 15120 cggcacccat tttttactgt aagtggaatc atgctgtccc tgttgtccta aatttatggg 15180 ggagattttc cttatctaca tatgtagata aaggtttaat cattaatgat taatgatttt 15240 gaagtactat aactgattta acccactggt cacttggact cttggtgtta acaaacattg 15300 ctgggttcag tgttgtccct tatgtctttg tgtacacttg atagattatt agaagcaaaa 15360 tcgtgccaaa tcaaaagaca atggatgttt taaattttgg tagatacagc tgggcgtgat 15420 tgctcacgcc tgtaatccca gcactttggg aggccaagac ggaaggatca cttgaggtca 15480

ggagttcgag accaacctgg ccaacatgtt aaaaccccca cctctgctaa aaatacagta 15540 gttagccggg tgtggtggtg cactcctgta gtcccagcta ctcaggaggc tgaggcatga 15600 gaattgcttg aaccegggaa geagaggttg eagtgageea agattgtgee actgeactte 15660 agcctgggta acagagtgag actctgtctc ccaaaaaaaa aaaaaaatta aaaaattatt 15720 ttttggtaga taactaccaa attgctgtct ataaagctgt cactttgctg gccttgactt 15780 aaqtqqcctc ttaqtacaca ctqccattaa cgtgggttga agttatctaa ccgttttcat 15840 ttccaatcac agatgtggtt aaaatctttt gaattttttt tttttttaat taaaaaagtt 15900 tgctcacgcc tgtaatccca gcacttgggg aggctgagct gggcggatca ctgaggtaag 15960 gagtttgaga ccaacttggc caagatggtg aaaccctgtc tctactaaaa atacaaaaat 16020 tagctgggca tggtggcaca tgactataat cccagctatt cgggaggctg aggcaggagg 16080 attgcttgaa cctgggaggt ggaggttgca gtgagccaag attgtgcctc tgcactccag 16140 cctgggcaac agaacaagac attgtctcca aaaaagaaaa aaaaaatatg tgtttttgta qaqctatqtt ttqctatatt qcccaggctg gtcttgaaga cctggcctca ggtgattctc 16260 caccttggtc tcccgaagtg ttgggattac aggcgtgagc caccacacct ggctcttttg 16320 aatgtttact gtacattttt agtctcttgt gaattgtctg tttaaatctt ttgtattttt 16380' ctactgaaat titticttac tgatggaaca titccttcct tccttccctc cctccctctc 16440 tecctecett estecettes titetteest sectestest steestest statesetes 16500 ttecctecte tectactect tecetectte ectecttect.tetectttet ttteccetec 16560 cagtattgcc caggccggac ttgaagtact ggtccttcca cctcagccta ttgagtagca 16680 tgctccactg cacgtagcct gatggaacgt tttgtaaata atcctcagtc tgtcatttgt 16740 ctttgtactt cattatggtg tcttctgcca tatagaaatt tagcatttaa tgtaaataat 16800 accaccttac ccgggcacgg tggctcacac ctgtaattcc agcactttgg gaagctgagg 16860 tgggcgcatt atgaggtcag gagatcaaga ccagcctgat caacatggtg aaaccccatc 16920 tctactaaaa atacaaaaat taaccgggca tggtggcgtg cacctgtaat cccagctcct 16980 caggaggctg aggcaggaga atcacttgaa cccaggaggt ggaggttgca gtgagccgag 17040 atcgcaccac tgcactccag cctgggtgac agtgagattc tgtctcaaaa aaaaaataat 17100 aataataatg ataataccac ctctccctca gaattgtatg ttgtacttag aaaggccttt 17160 17220 cctacttaaa taatgcaaaa gtatgctcta gtattttttt ctaggatttt tgtggctaaa atttttatct ttaattcatt taggacttat ttttggtata gaatgaggca aggacctgat 17280 tctttttccc ttatggggaa aaaaagtcac aatactattt atccaataat ttttttctta 17340

201

:. 1

tggaaatata attaacatgt ccatcaccat cacacctttt ctttcttctt cttcttttt 17400 cttgagaccg agtttcgcac ttgttgccca ggccggagtg cagtggcgca acttggccca ctgcaacctc tgcttcccgg gttcaagcga ttctcttgcc tcagcctccc aagtagctgg 17520 gactacaggt gcctgtcacc acgccctggc taatttttgc atttttagta gacacaaagt 17580 ttcgtcatgt tggccaggct ggtctcgaac tettgacetc aggtgatecg eccaectegg cctcccaaag tgctgggatt acaggcgtga gccaccgtgc ccagcctctg ctttttatta 17700 tatttttcct tttttttt ttctttttg ccttcctgtg cagaggaaac actatttct 17760 tctaaagctt ggtttctgct gaccagtagc aatttttaac atcagtctga tttccctctg 17820 tragectata ggetttgetg ggttatetet cetgactaat ttgtgtagea actteacatg 17880 aatttaaaca tttgtatcat cagttaacac tcactttgaa aatgttattg ggaggcttgt 17940 taagtcaggt gtattttgtg tgactgctct acactcaggc cttctggaaa ccctgcagag 18000 ggtagctcta gtggccagct agctctcttg ctgaaaatga gcaacataag tacatgaaaa 18060 acccaacaag taggatttga aagcggggct aattgtaccc ttatttcttc tggggataaa 18120 agtettaaac titgtttaaa gtaaaatgtt titattictg acggtgatit gtitcactta 18180 18240 cccgcaagtt ttgcccgtgc cgccttcctc cttgtgcctg cagggacatt tgctggtgtg 18300 gcagecteca ggccegtece cagecttttt ettggcacae ettetetagg atggetggga 18360 cagtgactta gettetacae etgtgaetaa ecatttteat tecattetae agetttgaea 18420 attattctgc caatgttatg gtagatggaa aaccggtgaa tctgggctta tgggatacag 18480 ctggacaaga agattatgac agattacgcc ccctatccta tccgcaaaca gtaaggattg 18540 cagctgactt ttaatgtgtc ttttagagta tataattctc gagcgcttaa ttagtgcatg 18600 ttacctatgg acttgcttat attgccatca tttgggtatt gagtaaatag caaacagggt 18660 gggattggtt ccatgtaaac atccccctag atgcaagccc aggggttttg tgttttgagc 18720 gttaccagct gttccattgt tgggcatttt acagtcttcc atttagcttt agaataaccg 18780 tatgaaagag ctactttttg tttttgcaaa ccagttttta acaccaatta gtttgaaggc 18840 aggtttgctg tgtgacattt ttgtaccaca gaatcaaatt aggcagttaa gattcaggtt 18900 totttaaacc aagttagtaa ctaatotoac aggtttaata catttttcc cacaaaatac 18960 ataatttgta tggattttgt gaaccataca atagaaccta aatttattca atgtagattg 19020 aagttttggt tttgtaaaat gtatccactg tgtctaatca gaaaaaaaag tttacttttg 19080 cttctgtatc agacaactaa gtgatttatt taccaaagct aattagagca gtagctggtg

			54/61			
aaaatgggt	a cttagaaga	c attgttgtc	g ttaaaagtta	a cttttcttt	a agcagcggtt	19200
ttacttgtg	t atcatttgc	t tatcttgtt:	a catgtttgtt	cttcatttt	aaaagtatct	19260
ttggaagca	a aagttaaat	a tgcttgagai	tccttgggtt	gataacctgt	gtgcatgtcc	19320
tagctctgtg	g acttcaggc	a ggcttcatco	c tctctccagt	ctttgcctgt	ttccttgtag	19380
ggtgagatga	a gtacgtgtc	a cgcacgcata	a acagtectgg	gcacatagca	a cacactgtgg	19440
ggccagccg	tgtcagaat	t ctcctgttcc	tcagtgtgcg	ggtgggtcgg	, cctaaagagt	19500
gctgctttc	acgttgtgc	caaatgagtg	gaagttgtgt	ggtgctcago	acacctgggt	19560
tggccggagg	gattggggtt	ggggttgggt	tgaggtcagg	aagacatcct	agagaaaggc	19620
tggctttgag	g ccctgattga	a tgatgaggca	gcctgtgatt	gattcaacca	gtacttcgtt	19680
gtaggggta	a atatgggtga	a aataacttag	tggttaagtc	tgctgtatta	aaaatcagtc	19740
tataatccc	: agacaattca	aattcttcag	tatcttagga	aactcttcta	tacccagtgg	19800
atgtttaata	attcagatto	, taaatggatt	taaaaacata	ctggctggta	gagtaggaga	19860
cttcagccca	ctggacacat	gtggaagggt	gtggtgtcat	tctgagaaac	aagagccacc	19920
ctgctgtgac	tcagggggta	ccgggcaggg	tgaggcctct	ctaaggaagg	cctcacagta	19980
agtcaagggt	gacttggcag	gagtcccact	ttgtgttctg	aggaacacac	agataaggaa	20040
agagaactct	cctcagcttg	aacaaagctg	tagagtgtga	cgcctggtat	caaagtaggt	20100
gttgtcctca	tagggctaga	acttaaactt	catgtttcct	ctgtgtgaga	ctgtggactg	20160
ctttcctata	aaatatttga	ggagcaaggg	agggagtggg	acatggttct	tgccctcagg	20220
tagttcacag	aaaagtccca	taaactgtgt	aagacaccct	gtgctagcaa	gggggtgagc	20280
		ggggcgagca				20340
		aattatcttg				20400
		tcatcccttt				20460
		ctgggtctct				20520
		ctgattgctg				20580
		cactctcctg				20640
		acatttcttg				20700
		tctgttcaga				20760
		tcttagttga				20820
		ttctcttgaa				20880
		aagtcttgtc				20940
tgtgtagatc	acctgtattt	atttgcctgc	ttgtaccagc	attggtggtg	tgagtgggag	21000

cctaagtgac ctgtcagtgt cacagcgagt cctgagccct gtgtgtgtcc tgagactcag gctgtgcagc gggttcgctg agatgctgag cctccatgtt ggggtcagcc aggaccccag tgcgtcatgc cagttgtttc attttctctc taggctaaaa gttgttgttg ttgttgttgt 21180 tgtttgagac agagtttcgc tcttgttgcc aggctggagt gcaatgggtg tgatcttggc 21240 tcactgcaac ctccgcttcc caggttcaag tgactttccc gccctagtct ctcaagtagc 21300 tgggactaca ggcatgtgct accatgcctg gctaattttg ttttgtattt tattttttt 21360 gagacagagc gagactctgt ctcaaaaaaa aaaaagaaaa caaagaaaaa agaaaagctt 21420 gagtgagatg aaattaaaat aattttctca ttttgagaca gggtctcgct ctgtcaccca 21480 gactggagtg cagtgtcaca atctcgcctc actgcaacct ccacctcccg ggttcaagca 21540 gttetetgee teagectece gagtagetgg gattacaggt geetgeeace atgeeegget 21600 aattttttgt atttttagta gacacagggt ttcaccatct tggccaggtt ggccttgaac 21660 tcctgacctc gtgatccacc tgcctcggcc tcccaaggtg ttgggattag aggcgtgagc 21720 gcttttctta aaagagttcc agggttctat gttggaagag cgagtttgtc agtttttatt 21780 ggaacaaaga aatgaattga cagcattgtg ataaacactg gaagtgtcac ttctaaaatt 21840 tgtccatggc tgaaagtggt ggctcatgcc tgtaatccca gcacgttggg aagccaaggt 21900 gggtggagca cctgaggtca agagtttgag accagcctgg ccaacatggt gaaacctggt 21960 ctctactaaa aatacaaaaa attagctggg cgtggtggtg tgtgcctgta gtcccagcta 22020 cttgggaggc taaggcagga gaatcgcttg aacccaggag gcagaggttg cagtgagctg 22080 agateteace attgeactee ageetgggea acagageaag acteegtete aaaaaegett 22140 gtccttaagg ggtggcttcc cccagaccta caaagtagcc cagaattgga ggtcttagtg 22200 tcagcaacag tgctgatttt gataatgcaa gtctgtacat tcaaaccagt ctcccagaac 22260 taggtggaag ataggaacat ttctgcatag gagacttgga atgttctggc agcattaaaa 22320 ccctgaggcc cggctatgtt ctgggagagc cctttggcag gcatcattta cagacgggtc 22380 cttttectgt atgetgtggc ttcaactagg ctgtgtctga gaactcggat ggagcacttg 22440 aaagtgcccg tggctcccgc ctgcctttgc ggtaagggac agtgcagaac atctccggct 22500 gtgccagctg ttgtagattc tggtgggtgc tgccatggga ggaggagcac gttgttgccc 22560 coccteagga tetecetgae etetgtette accategttg aacttaaege etgettttga 22620 ccaggtagcg tggagtgttt cagtggcatt tgtcatcgaa gatatgttag aatctattgt 22680 atgettttgg ateteteegg agggttaaga caaaatteta ataaagaate gataagaggt tatattgatt tttgttgtcc tcagtctgta ctaaactcaa accaagttct catgcattac 22800

taggttggag aaacgtacgg taaggatata acctcccggg gcaaagacaa gccgattgcc 22860 gtatgtaaaa ctttcagtcc acttcagttt caagctttct ctgttctctc atttcactte gttttcctag gatttttat taagcctcaa gctccttgag tgttttatat ttaattcact 22980 caaggttggg gttttgcttg atgaaataaa cttcattaga gtgtgatagt ttacccaccg 23040 gcttgaatta aagcagtttg tgaactgtga tcttctcctc ccaagtgaaa ggaggggaca 23100 gtgagagggc ccctctcctg gctggttgga gatgcagata tggagactcc tcccggaage 23160 ccacctggct gtgagecgag ecggageagg accaacettg ttgeegggge ettettete 23220 cgcttgggtg tecegtgtgg tggggctgtc tggggcgtggc tgtgcagtgc tgctgagcta 23280 accecacegt gettgagatg gtgtgetggg tgeegeggtg attettggae gagettgtge 23340 atgcgccagc actcttcaaa tgccagttat aaaaagctgt tgtgtgggat gtttctttcc 23400 ctttcaggta caaggtatca gctggagggt tgaaagtgta gcttgggaat tgtgtgcatt 23460 tcataaagta gcataattgc ctttttccag gagaatattt tagaaatcta gcattttaga 23520 attettggge atttttaaat acaggtgaat atttgaattt ggtttgacac aaaatacaga 23580 atggatgaag catgcagatg titggcgtgt gccccgaagc accctctact ctgtcctctg 23640 cacccaccct ttgcgcctct gcgtcagcca cagctgcccc gggagcgagt tctcctgagg 23700 ccctggctgt gctgactcta gggcagcgtg agggtggttg tcagctgtga aggtgccact 23760 tacacactaa gtcctccttc cttgtggagg gaagggctca agtagcaaat attggagccc 23820 ccgcttggtg ctgggagctg tgacaggcag ctcctgaaga agcagtttaa ttggaaccag 23880 tgaccatcta aaactgtttg tactctaaac cagattttac agaaatattg gaatcatacc 23940 tttatacttg atttttctt tttagatagt taggcgtaaa ggaagcctcc tgagggtctg 24000 gtctgatcct cctgatcctt gaagagcttc cagcatcatt ctcccttcat gctccccatt 24060 aaagggtgga tcaggaagcg tctgaccaca ccactggtag acacgctctg cgtccaacaa gtccttccca gcaacatgta gaaagcaaag tgcatgcttc attctaaggt tgttgtctaa atgtttccct gtgtttcctt tttgtaggat gtgttcttaa tttgcttttc ccttgtgagt cctgcatcat ttgaaaatgt ccgtgcaaag gtaggtgggg atttaaaatg tgtatgtaag ttatagaatg atceteteag aaataaatae tttaaaatat caettageet aggaattttt agttatttaa attggtttta gcaatttgct acttaggtac atgattgggt ttttttttt cttttgagac ggaggtetca ctetgttgtg tecaggetgg agttgtactg gtgacateag ageteactgt ageettgaae teetgggete aaacagttet eetgeeceag eeteetgagt tgctgggacc ataaatgtgc accaccatgc gtggctaatc ttaaaagaat ttttgtatgg 24660

ctggttttgt agaccctggc ttgtctcaaa ctcctgggtt gaagtgatct ttcagcttca gcctcccaaa gtggtgggat tatagctgtg agccactgca tctggcccat cagcagttta 24780 ttttatttat ttattttga gagagtcttt ttttttgctt ttgtttttgt ttttgagatg 24840 gagtttcact cttgttgccc aggctggagt gcagtgacgc aatcttggct cactgcaact 24900 tecgeeteet gggtteaagt gatteteatg ceteageete eegagtaget gggattaeag 24960 gcatgcacca ccacgcccgg ctaattttgt atttttagta gaaatgtggt ttctccacgt 25020 cagtcaggct ggtctcgaac tcccgacctc aggtgatccg cgcgtctcgg cctcccaaag 25080 tgctgggatt acaggcgtgg gccaccgtgc ccggctgaga cagaatcttg cgctgtcatc 25140 caagetggag tgcagtggca caatettggg teactgcaae etececetee eggttcaage 25200 aattctcctg cctcagcctt cttagtagct gggattacag gtgcccgaca acacacctgg 25260 ctaatttttg tacttttagt agagacgggg tttcaccatg tttgccaggc tggtctcgaa 25320 cccctggcct caagtgatcc acccgccgca gactcccaga gtgctgggat ttcaggtgtg 25380 agccactatg cccggcctaa tacgtggatt tttaaagctt caggttctgg ttcagaagtt 25440 teetgggtet cattaaaata atgaggeact cagaattggt etaataaaaa taaegaeeat 25500 ttetttetae tecagtetet tteacaaact tettagtgaa aatgacaagt gaggeeette 25560 agtaggggca tittcagtgg agataatagc ggcagacctg agaccttggg ctaggtagtt 25620 tattctcatt tctgaacaga tgatgaattt tctcagatga ccctaagaaa ttgttttacc 25680 aaaaacaaag tgatctattt getttgggag gaactcectt cettttgttt etetteeett 25740 cccccctcc cctgcggttg tagagcccgt tctgtccggt cgtggttctg tccagccatg 25800 atccgggagt cctagcttgc taatggaaca cctgagatgt tccttatggc tcaaggcttg 25860 aattgaaggt gggaaccacc tgaagcctcc gtggggaggc cttgcctgag gttaggtgtc 25920 tggcatgagt gccgccggct gggtgtgatt taggtgaagg acatctgtaa aggagcgtgt 25980 cacaacctct gttccttctt cacatctagt ggtatcctga ggtgcggcac cactgtccca 26040 acacteceat catectagtg ggaactaaac ttgatettag ggatgataaa gacaegateg 26100 agaaactgaa ggagaagaag ctgactccca tcacctatcc gcagggtcta gccatggcta 26160 aggagattgg tatggaatcc tgtgtttttc ctcctccttg tacctctttt attgtagtga 26220 cagagactgg agtecagtet gggaaaggag ggtgtgtgtc teccaeteag ggeetggtgt 26280 actcttgggg aaccagctgg caaggccctg tgggtcttaa cgtcagcgtt ggaaggtgga 26340 agcagggetg ggagceggea gaaggegeee gggeeeeagg agetgeetee egetggtggt 26400 gtgatcagaa gagagtgggg tcgagtgtac attgccgtgt ggtcgtgttt cctgtaggtg 26460

ctgtaaaata cctggagtgc tcggcgctca cacagcgagg cctcaagaca gtgtttgacg 26520 aagcgatccg agcagtcctc tgcccgcctc ccgtgaagaa gaggaagaga aaatgcctgc 26580 tgttgtaaat gtctcagccc ctcgttcttg gtcctgtccc ttggaacctt tgtacgcttt 26640 caatgccaac tttttgttac agattaattt ttccataaaa ccattttttg aaccaatcag taattttaag gttttgtttg ttctaaatgt aagagttcag actcacattc tattaaaatt 26820 tagccctaaa atgacaagcc ttcttaaagc cttatttttc aaaagcgccc ccccattct 26880 tgttcagatt aagagttgcc aaaatacctt ctgaactaca ctgcattgtt gtgccgagaa 26940 caccgagcac tgaactttgc aaagaccttc gtctttgaga agacggtagc ttctgcagtt 27000 aggaggtgca gacacttgct ctcctatgta gttctcagat gcgtaaagca gaacagcctc 27060 ccgaatgaag cgttgccatt gaactcacca gtgagttagc agcacgtgtt cccgacataa 27120 cattgtactg taatggagtg agcgtagcag ctcagctctt tggatcagtc tttgtgattt 27180 catagogagt tttctgacca gottttgcgg agattttgaa cagaactgct atttcctcta 27240 atgaagaatt ctgtttagct gtgggtgtgc cgggtggggt gtgtgtgatc aaaggacaaa 27300 gacagtattt tgacaaaata cgaagtggag atttacacta cattgtacaa ggaatgaaag 27360 tgtcacgggt aaaaactcta aaaggttaat ttctgtcaaa tgcagtagat gatgaaagaa aggttggtat tatcaggaaa tgttttctta agcttttcct ttctcttaca cctgccatgc ctccccaaat tgggcattta attcatcttt aaactggttg ttctgttagt cgctaactta 27540 gtaagtgett ttettataga acceettetg actgageaat atgeeteett gtattataaa 27600 atctttctga taatgcatta gaaggttttt ttgtcgatta gtaaaagtgc tttccatgtt 27660 actttattca gagctaataa gtgctttcct tagttttcta gtaactaggt gtaaaaatca 27720 tgtgttgcag ctttatagtt tttaaaatat tttagataat tcttaaacta tgaaccttct 27780 taacatcact gtcttgccag attaccgaca ctgtcacttg accaatactg accctcttta 27840 cetegeceae geggacaeae geeteetgta gtegetttge etattgatgt teetttgggt 27900 ctgtgaggtt ctgtaaactg tgctagtgct gacgatgttc tgtacaactt aactcactgg 27960 cgagaataca gcgtgggacc cttcagccac tacaacagaa ttttttaaat tgacagttgc 28020 agaattgtgg agtgttttta cattgatctt ttgctaatgc aattagcatt atgttttgca 28080 tgtatgactt aataaatcct tgaatcatac gactggtaat actggtgttt ttgagacttg 28140 atgaacaagt teetggtgtg tgtttgtttg cettgettta aagteetggg ttgttggaga 28200 cagtcatttt caatgcgtgt ctccacacag gagggacagg gagtgccacc tccaggggag 28260 aactgggtga gcccaaatac ggcaggagtg gaggtgacat tcatgtttgg acctgtcgaa

....

cagtegegaa getetgaggg agaagegeet ateggggtgt gtgtgeacat cetggeecag 28380 agetagggge tgaagatgga gatgttggga ecetagaetg geeetggaag agtagaggtt 28440 ggtgaaceae atgeeettaa gateetttee agaaggetgag tgegtggett aegeetetaa 28500 geeegaeget ttgggagget gacacaggag gagegettaa geeeaggag tetagaecag 28560 eetggae

<210> 24

<211> 211

<212> PRT

<213> homo sapiens

<400> 24

Met Gln Ala Ile Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys
1 10 15

Thr Cys Leu Leu Ile Ser Tyr Thr Thr Asn Ala Phe Pro Gly Glu Tyr 20 25 30

Ile Pro Thr Val Phe Asp Asn Tyr Ser Ala Asn Val Met Val Asp Gly 35 40 45

Lys Pro Val Asn Leu Gly Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr 50 55 60

Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Val Gly Glu Thr Tyr 65 70 75 80

Gly Lys Asp Ile Thr Ser Arg Gly Lys Asp Lys Pro Ile Ala Asp Val 85 90 95

Phe Leu Ile Cys Phe Ser Leu Val Ser Pro Ala Ser Phe Glu Asn Val

Arg Ala Lys Trp Tyr Pro Glu Val Arg His His Cys Pro Asn Thr Pro 115 120 125

Ile Ile Leu Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr
130 140

Ile Glu Lys Leu Lys Glu Lys Lys Leu Thr Pro Ile Thr Tyr Pro Gln
145 150 155 160

Gly Leu Ala Met Ala Lys Glu Ile Gly Ala Val Lys Tyr Leu Glu Cys 165 170 175

Ser Ala Leu Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile 180 185 190

Arg Ala Val Leu Cys Pro Pro Pro Val Lys Lys Arg Lys Arg Lys Cys
195 200 205

Leu Leu Leu 210

<210> 25 <211> 192

212>	PRT	
213>	Homo	sapiens

.;

à,

Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Asp Val Phe Leu Ile
65 70 75 80

Cys Phe Ser Leu Val Ser Pro Ala Ser Phe Glu Asn Val Arg Ala Lys 85 90 95

Trp Tyr Pro Glu Val Arg His His Cys Pro Asn Thr Pro Ile Ile Leu 100 105 110

Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr Ile Glu Lys
115 120 125

Leu Lys Glu Lys Lys Leu Thr Pro Ile Thr Tyr Pro Gln Gly Leu Ala 130 135 140

Met Ala Lys Glu Ile Gly Ala Val Lys Tyr Leu Glu Cys Ser Ala Leu 145 150 155 160

Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile Arg Ala Val

Leu Cys Pro Pro Pro Val Lys Lys Arg Lys Arg Lys Cys Leu Leu Leu 180 185 190

<210> 26

<211> 579

<212> DNA

<213> Homo sapiens

<400> 26

atgraggera teaagtgtg ggtgggga gatggggerg tgggeaagae etgeettete 60
atcagetaca ceaceaacge ettteeegga gagtacatee eeacegtgtt tgacaactat 120
teagecaatg tgatggtgga cageaageea gtgaacetgg ggetgtggga caetgetggg 180
caggaggaet acgacegtet eeggeegete teetateeae agaeggaegt etteeteate 240
tgetteteee tegteageee ageetettat gagaacgtee gegeeaagtg gtteeeagaa 300
gtgeggeace actgeeeag cacacecate ateetggtgg geaceaaget ggaeetgegg 360
gaegaeaagg acaceatega gaaactgaag gagaagaage tggeteeeat cacetaeeeg 420

480

540

579

cagggcctgg cactggccaa ggagattgac teggtgaaat acctggagtg ctcagccc	tc
acceagagag geetgaaaac egtgttegae gaggeeatee gggeegtget gtgeeete	ag
cccacgegge agcagaageg egeetgeage etectetag	
<210> 27 <211> 192 <212> PRT <213> Homo sapiens	
<pre><400> 27 Met Gln Ala Ile Lys Cys Val Val Val Gly Asp Gly Ala Val Gly Lys 1</pre>	
Thr Cys Leu Ile Ser Tyr Thr Thr Asn Ala Phe Pro Gly Glu Tyr 20 25 30	
Ile Pro Thr Val Phe Asp Asn Tyr Ser Ala Asn Val Met Val Asp Ser 35 - 40 45	
Lys Pro Val Asn Leu Gly Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr 50 55 60	
Asp Arg Leu Arg Pro Leu Ser Tyr Pro Gln Thr Asp Val Phe Leu Ile 65 70 75 80	
Cys Phe Ser Leu Val Ser Pro Ala Ser Tyr Glu Asn Val Arg Ala Lys 85 90 95	
Trp Phe Pro Glu Val Arg His His Cys Pro Ser Thr Pro Ile Ile Leu 100 105 110	
Val Gly Thr Lys Leu Asp Leu Arg Asp Asp Lys Asp Thr Ile Glu Lys 115 120 125	
Leu Lys Glu Lys Lys Leu Ala Pro Ile Thr Tyr Pro Gln Gly Leu Ala 130 135 140	
Leu Ala Lys Glu Ile Asp Ser Val Lys Tyr Leu Glu Cys Ser Ala Leu 145 150 155 160	
Thr Gln Arg Gly Leu Lys Thr Val Phe Asp Glu Ala Ile Arg Ala Val 165 170 175	
Leu Cys Pro Gln Pro Thr Arg Gln Gln Lys Arg Ala Cys Ser Leu Leu 180 185 190	

International application No.

PCT/SE 03/00618

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12Q 1/26, A61K 31/03, A61K 31/12, A61P 3/10
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12Q, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5763496 A (JAMES ARTHUR HOLLAND), 9 June 1998 (09.06.98), column 2, line 4 - line 8; column 10	1-26
Х	US 5902831 A (JAMES ARTHUR HOLLAND ET AL), 11 May 1999 (11.05.99), column 14"conclusion", column 9	1-26
ĺ		
x	Diabetes, Vol. 49, November 2000, Toyoshi Inoguchi et al: "High Glucose Level and Free Fatty Acid Stimulate Reactive Oxygen Species Production Through Protein Kinase C-Dependent Activation of NAD(P)H Oxidase in Cultured Vascular Cells", page 1939 - page 1945, figure 3, page 1940	1-26
		
ļ		

X	Further documents are listed in the continuation of Box C	-	X See patent family annex.
*	Special categories of cited documents:	PT. 1	
'A'	document defining the general state of the art which is not considered to be of particular relevance		later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
'E'	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance: the claimed invention cannot be
'L"	document which may throw doubts on priority claim(s) or which is		considered novel or cannot be considered to involve an inventive

step when the document is taken alone cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other

document published prior to the international filing date but later than the priority date claimed

Further documents are listed in the continuation of Box C.

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 2 2 -07- 2003 <u>21 July 2003</u> Name and mailing address of the ISA/ Authorized officer

Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86

Carl-Olof Gustafsson/EÖ Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/SE 03/00618	0618	03/0	/SE	PCT/
-----------------	------	------	-----	------

C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*		Relevant to claim N
Х	WO 017533 A1 (HENRY FORD HEALTH SYSTEM), 15 March 2001 (15.03.01), pages 6-8, page 8, lines 1-11, claims	9,16
A	WO 9912539 A1 (THE JOHNS HOPKINS UNIVERSITY SCHOOL O MEDICINE), 18 March 1999 (18.03.99)	9,16
A	US 2001019832 A1 (MARGUERITE LUTHMAN), 6 Sept 2001 (06.09.01), examples 1-4, claims	1-26
	· 	
		•
		N,
	•	
n PCT/ISA	J210 (continuation of second sheet) (July 1998)	

International application No. PCT/SE03/00618

Box 1	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This inte	mational search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. 🛛	Claims Nos.: 9-25 because they relate to subject matter not required to be searched by this Authority, namely:
	see next sheet
2.	Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
	·
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inter	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark o	on Protest
	No protest accompanied the payment of additional search fees.
Came DOTTE	SAPIO (continue de la continue de la

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

International application No. PCT/SE03/00618

Claims 9-25 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Form PCT/ISA/210 (extra sheet) (July 1998)

International application No. PCT/SE 03/00618

D.						1-1-1-1-1-1
cited	atent document d in search report		Publication date		Patent family member(s)	Publication date
US	5763496	A	09/06/98	TA	189957 T	15/03/00
				ÜA	1085997 A	19/06/97
	•			CA	2238098 A,C	05/06/97
				CA	2309881 A	05/06/97
				DE	69606882 D,T	17/08/00
				EP	0861070 A,B	02/09/98
				SE	0861070 X,B	UL/ U3/ 30
				EP	0914821 A	12/05/99
				ES	2144792 T	16/06/00
				GR	3033067 T	31/08/00
				JP	11507946 T	13/07/99
				บร	5902831 A	11/05/99
				WO	9719679 A	05/06/97
					~~~~~~~~~~~~~~~~~	וביסטינט
บร	5902831	A	11/05/99	AT	189957 T	15/03/00
	F			AU	1085997 A	19/06/97
				CA	2238098 A,C	05/06/97
				CA	2309881 A	05/06/97
				DE	69606882 D,T	17/08/00
				EP	0861070 A,B	02/09/98
				SE	0861070 T3	
				EP	0914821 A	12/05/99
				ES	2144792 T	16/06/00
				GR	3033067 T	31/08/00
				JP	11507946 T	13/07/99
				US	5763496 A	09/06/98
				WO	9719679 A	05/06/97
WO	017533	A1	15/03/01	NONE		
WO	9912539	A1	18/03/99	A11	0000100 4	
	JJ65444	7.1	10/03/33	UA US	9226198 A	29/03/99
				U3	6090851 A	18/07/00
US	2001019832	A1	06/09/01	AU	4131601 A	12/09/01
				AU	4632100 A	10/11/00
				CA	2399889 A	07/09/01
	•			ED	1101750 4	
	•			EP	1181750 A	27/02/02
				EP	1259232 A	27/11/02
	·			EP JP	1259232 A 2002543597 T	27/11/02 17/12/02
-	·			EP	1259232 A	27/11/02

Form PCI/ISA/210 (patent family annex) (July 1998)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

# IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)